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Abstract 24 
Metabolic resistance to insecticides in mosquitoes threatens malaria control. Unless it is 25 
managed, recent gains in reducing malaria transmission could be lost. To improve monitoring 26 
and assess the impact of this resistance on control interventions, we elucidated the molecular 27 
basis of pyrethroid resistance in the major African vector, Anopheles funestus in southern 28 
Africa, showing that a single cytochrome P450 allele (CYP6P9a) is reducing bednet efficacy. 29 
Key resistance genes are detected Africa-wide, but vary geographically. Signatures of selection 30 
and adaptive evolutionary traits including structural polymorphisms and cis-regulatory 31 
transcription factor binding sites were detected with evidence of selection by insecticide-treated 32 
nets scale-up. A cis-regulatory polymorphism driving the over-expression of the major 33 
resistance gene CYP6P9a allowed us to design the first DNA-based diagnostic assay for P450-34 
mediated pyrethroid resistance. Using this tool to detect and track the spread of resistance 35 
revealed that it is almost fixed in southern Africa but absent elsewhere. Furthermore, 36 
experimental hut studies demonstrated that CYP6P9a-Resistant mosquitoes survived and 37 
succeeded in blood-feeding significantly more than susceptible individuals, highlighting the 38 
urgent need to introduce new generations of insecticide-treated nets that are not reliant on 39 
pyrethroids. 40 
 41 
One Sentence Summary: First DNA marker for P450-mediated pyrethroid resistance in 42 
malaria vectors enables to show that metabolic resistance is reducing bednet’s efficacy. 43 
 44 
  45 
 46 
Introduction 47 
Malaria prevention relies heavily on the use of insecticide-based vector control 48 
interventions, notably pyrethroid-based Long Lasting Insecticidal Nets (LLINs). These tools 49 
have been credited with more than 70% of the decrease in malaria mortality in the past 15 years, 50 
having helped avert more than 663 million clinical cases of malaria (1). However, resistance to 51 
insecticides, particularly pyrethroids, in malaria vectors threatens their continued effectiveness. 52 
Unless it is managed, the recent gains in reducing malaria transmission could be lost (2). 53 
Elucidating the genetic basis and evolution of resistance is crucial to design resistance 54 
management strategies and prevent malaria resurgence (2).  55 
Without genetic information on insecticide resistance genes and associated molecular 56 
markers, it is difficult to track and anticipate the course of resistance or assess its impact on 57 
malaria transmission and on the effectiveness of control tools such as LLINs. The current 58 
inability to track metabolic resistance in this way in all major African malaria vectors including 59 
Anopheles gambiae and Anopheles funestus is a major obstacle to the design of rational, 60 
evidence-based resistance management strategies. Of the four classes of insecticides used in 61 
public health, pyrethroids are by far the most widely used and the main class recommended for 62 
use in insecticide-treated nets. Therefore, understanding the mechanisms conferring pyrethroid 63 
resistance in mosquitoes is of critical importance.   64 
Two major causes of insecticide resistance are metabolic resistance and target-site 65 
insensitivity (3). Unlike target-site resistance (e.g. knockdown resistance: kdr), metabolic 66 
resistance remains less characterized despite posing a greater risk to control interventions (4). 67 
Although candidate resistance genes have been detected (5-8), it has proved difficult to dissect 68 
the molecular bases of metabolic resistance and detect associated molecular markers, because 69 
of the size of detoxification gene families, redundancy among their members and the multiple 70 
mechanisms through which metabolic resistance can arise (9). Cytochrome P450 71 
monooxygenases have consistently been associated with pyrethroid resistance but, unlike kdr, 72 
no DNA-based marker has yet been detected to track P450-mediated resistance and assess its 73 
impact on malaria control tools.  74 
Here, we elucidated the complex molecular basis and genomic evolution of metabolic 75 
resistance to pyrethroids in the major African malaria vector An. funestus. We detected key 76 
DNA-based markers to design a field-applicable diagnostic assay to track this resistance and 77 
used it to demonstrat that this metabolic resistance reduces the efficacy of insecticide-treated 78 
nets. 79 
 80 
Results 81 
RNAseq transcriptional profiling of mosquitoes from across Africa identifies 82 
candidate pyrethroid-resistance associated genes  83 
To identify genes associated with pyrethroid resistance in Anopheles funestus Africa-84 
wide, we performed RNAseq-based transcriptional profiling of mosquitoes from four different 85 
African regions: southern (Malawi), East (Uganda), West (Ghana) and Central (Cameroon), in 86 
comparison to a laboratory colony (FANG) that is fully susceptible to all insecticides.  87 
Pronounced differences in the expression of key candidate genes were observed between the 88 
four regions (Fig. 1A-C, Fig. S1A-E, Table S1).  89 
Cytochrome P450s were frequently significantly over-expressed (adjusted p value 90 
<0.05)(Text S1), with CYP6P9a (AFUN015792; 60.5x) and CYP6P9b (AFUN015889; 23.9x) 91 
showing extreme over-expression in Malawi compared to other regions (<7x) (Fig 1B-C). Other 92 
P450s were more over-expressed in one region than in others (Figure 1B-C) including CYP9K1 93 
(AFUN007549) which was highly over-expressed in Uganda (5.2x) and moderately so in 94 
Ghana (2.9x), but not in Malawi or Cameroon. CYP6P5 (AFUN015888) was significantly over-95 
expressed in Ghana (6.3x), Cameroon (5.8x) and Uganda (4.1x) but not in Malawi. The 96 
duplicated CYP6P4a and CYP6P4b are highly over-expressed in Ghana (44.8x and 23.9x 97 
respectively), moderately so in Malawi and Uganda (<6x) and not in Cameroon. CYP325A is 98 
highly over-expressed in Cameroon (26.9x) but less so in other regions (<6x). Other P450s are 99 
moderatey over-expressed, including two paralogous CYP9J11 genes and CYP6N1, up-100 
regulated in southern and West Africa, whereas CYP315A1 is over-expressed in all sites but 101 
Malawi. Other detoxification-associated gene families are also over-expressed (Text S1) 102 
including a cluster of glutathione S-transferase epsilon genes (GSTe1, GSTe3, GSTe5 and 103 
GSTe2, a known DDT resistance gene (10)) up-regulated in all regions except East Africa (Text 104 
S1). Analysis of Gene Ontology enrichment (Fig. S2A-C) further confirmed these regional 105 
differences. 106 
Quantitative RT-PCR with fifteen genes confirmed these regional differences, with a 107 
high and significant correlation observed between qRT-PCR and RNAseq results for the 4 108 
countries when compared to FANG (R2=0.695; P<0.001) (Fig. 1E; Fig S3A to C; Text S1).  109 
Overall, gene expression analyses underlined the importance of P450 monooxygenases 110 
in pyrethroid resistance and identified heterogeneities in gene expression among populations 111 
from different geographical regions. Notably, the most extreme differences in expression 112 
profiles among samples were observed in members of a cluster of CYP6 genes in the rp1 113 
pyrethroid resistance Quantitative Trait Locus (QTL): the southern African mosquitoes showed 114 
massive over-expression of CYP6P9a and CYP6P9b, while West African mosquitoes from 115 
Ghana showed over-expression of CYP6P5 and CYP6P4a/b. These differences suggest that the 116 
molecular bases of pyrethroid resistance may vary across Africa, possibly due to a combination 117 
of variation in selective pressures and restricted gene flow among regions (11, 12). 118 
 119 
Whole genome polymorphism analysis of field collected mosquitoes identifies 120 
selective sweeps associated with insecticide resistance loci  121 
Because metabolic resistance could be conferred by point mutations in coding and 122 
cis/trans regulatory regions, we scanned the whole genome for pyrethroid resistance-related 123 
signatures of selective sweeps in the highly pyrethroid resistant population from Malawi, to 124 
detect resistance loci. We performed pooled-template whole genome sequencing on field-125 
collected population samples  from southern Africa where high levels degree of expression of 126 
CYP6P9a and CYP6P9b have been observed. We also comparatively assessed the genomes and 127 
compared these to samples of the laboratory resistant FUMOZ-R and the susceptible FANG 128 
strains. We detected contrasting patterns of polymorphism between these strains and also 129 
between pre- (MWI-2002) and post-bednet intervention (MWI-2014) samples from Malawi 130 
(Fig. 2A; Table S3). The major selective sweep for both Malawi and FUMOZ-R was on scaffold 131 
KB119169 spanning the rp1 pyrethroid resistance region on chromosome  arm 2R (Fig. 2B). 132 
Plotting minor allele frequencies across the region revealed a valley of reduced genetic diversity 133 
around the cluster of P450s on the rp1 pyrethroid resistance QTL correlating a selected rp1 134 
haplotype with CYP6P9a over-expression (Fig. 1D). This selective sweep appears to be at or 135 
near fixation in a contemporary Malawian population (as well as in FUMOZ-R) with little 136 
diversity observed around the P450 cluster in this highly pyrethroid resistant population (Fig. 137 
2B). No reduced diversity was observed in the susceptible FANG strain, suggesting an 138 
association between this selective sweep and pyrethroid resistance in line with the very low 139 
CYP6P9a expression in FANG (Fig. 2A-B). These results are consistent with previous reports 140 
of selection on highly over-expressed resistance genes (8). 141 
Complex evolution of the gene cluster of the rp1 CYP6 genes associated with 142 
pyrethroid resistance  143 
As rp1 was consistently associated with pyrethroid resistance, a fine-scale analysis of 144 
this locus (120kb) was performed, revealing evidence of complex molecular evolution likely 145 
under insecticide-driven selection. 146 
Inspection of pooled-template whole genome alignments showed two anomalous 147 
features in the 8.2kb sequence between CYP6P9a and CYP6P9b. In some samples, the coverage 148 
depth was greater than for the surrounding sequence and some samples showed read pairs in 149 
the correct relative orientation but with greater than expected insert sizes. This is indicative of 150 
a large indel: a “deletion” in the sequenced genome(s) or an “insertion” in the reference genome 151 
(Fig. S4A). This insertion corresponds to 6545 bp and appears fixed in the FUMOZ colony 152 
sample with evidences that the inserted sequence is homologous to another region nearby (on 153 
the same assembly scaffold) in the genome (Fig. S4B). In contrast, the FANG susceptible strain 154 
shows evidence of the “deletion” form of the indel (Fig. S4A). This insertion, nearly fixed 155 
across southern Africa (26/27), is absent elsewhere in the continent where only a 1.7kb 156 
intergenic region is observed after PCR (Table S4). RNAseq data showed that the inserted 157 
region is a transcribed region, showing evidence of splicing and containing three micro-RNAs, 158 
but no P450s.  159 
We assessed the composition of this 6.5kb insert to elucidate its role by sequencing the 160 
full 8.2kb CYP6P9a/b intergenic region and analysing it using GPminer (13). This insert 161 
contains abundant binding sites for transcription factors including a CpG island (1.3kb), several 162 
GATA, TATA (35), CCAAT (12) and GC (11) boxes and over-represented oligonucleotides. 163 
It also contains several binding sites for key transcription factors associated with xenobiotic 164 
detoxification, including Cap-n-Collar-C (CnCC) (51 sites) and Muscle aponeurosis 165 
fibromatosis (Maf), suggesting that this insertion may drive CYP6P9a/b over-expression. The 166 
insert also contains a microsatellite (FUNR) between 6082bp and 6482bp, only 80bp from the 167 
5’ untranslated region (UTR) of CYP6P9a. Previous genotyping of this marker Africa-wide 168 
revealed marked differences associated with pyrethroid resistance profile (11). FUNR is not 169 
present within the 1.7kb intergenic region between CYP6P9a and CYP6P9b in the susceptible 170 
FANG strain. It has been shown that microsatellite loci are involved in upregulation of P450 to 171 
confer insecticide resistance in other insects such as aphids (14). It has also been shown in Yeast 172 
that polymorphic tandem repeats in the promoter regions can activate gene expression by 173 
impacting local chromatin structure to act as “evolutionary tuning knobs” to drive rapid 174 
evolution of gene expression such in a case of insecticide resistance selection.  175 
Polymorphism of CYP6P9a regulatory region associated with pyrethroid 176 
resistance 177 
Polymorphism of CYP6P9a 5’ UTR and upstream region Africa-wide: To detect 178 
cis-regulatory mutations controlling CYP6P9a/b-based pyrethroid resistance, we compared 179 
800bp immediately upstream of CYP6P9a Africa-wide. Several locations exhibited a very low 180 
or no polymorphism (Fig. S5A). The sample with the highest diversity was the fully susceptible 181 
FANG with the highest diversity indexes supporting the selection acting on this gene in field 182 
resistant populations. Despite low diversity observed in different regions, southern Africa 183 
populations consistently exhibited a different polymorphism pattern to other regions including 184 
the presence of an AA insertion 8bp upstream of a putative CCAAT box present only in 185 
southern African samples through an A/C substitution. The AA insertion located 359 bp from 186 
start codon is tightly associated with other polymorphisms in a haplotype (STH10) which is 187 
nearly fixed in southern Africa (63/68) reflecting the marked selective sweep observed around 188 
this gene in this region. Analysis of the phylogenetic tree revealed four clusters of haplotypes 189 
from different regions notably southern Africa (Malawi, Mozambique and Zambia plus 190 
FUMOZ-R), East-Central (Kenya, Uganda and Cameroon), West (Ghana) and West-Central 191 
(Benin and Congo) (Fig. 3A). The FANG susceptible strain forms its own cluster divergent 192 
from the others.  193 
Closer analysis of the haplotypes using a haplotype network confirmed the presence of 194 
4 major haplotypes corresponding to these geographical clusters, STH10 in southern, 195 
EST/CNT24 in East-Central, BEN/DRC21 in West-Central and GHA11 in Ghana only (West) 196 
(Fig. 3B). Surprisingly, the other 3 regions also exhibit predominant haplotype in the 197 
populations to near fixation contrary to previous data where they were more polymorphic (11). 198 
This result suggests that resistance to pyrethroid beyond southern Africa could have also been 199 
selected through CYP6P9a or other genes in the vicinity on the rp1 QTL regions. The 200 
hypothesis of a possible hitchhiking effect here rather than the direct involvement of CYP6P9a 201 
is supported by the important differences observed between the four major haplotypes with 202 
more than 20 mutational steps of difference between them. Therefore, it is very likely that 203 
resistance conferred by the rp1 locus occurred through independent selective events with likely 204 
different genes. This is supported by RNAseq data showing that although rp1 genes are over-205 
expressed Africa-wide the main genes are different with CYP6P4a predominant in Ghana but 206 
not in others, CYP6P5 in Cameroon and Uganda whereas CYP6P9a is the major gene in 207 
southern Africa. The neighbor-joining phylogenetic tree of the Nst genetic distances between 208 
different countries (Fig. 3C) correlated with the polymorphism patterns showing countries 209 
clustering according to the haplotypes diversity pattern from ML tree or the TCS network. 210 
Scaled-up use of insecticide-treated nets has selected for changes in the regulatory 211 
region of CYP6P9a: To assess whether the differences observed in the 5’UTR and upstream 212 
region of CYP6P9a between southern Africa and other regions was a result of selective pressure 213 
from insecticides, we compared samples from southern Africa before the scale-up of 214 
insecticide-based interventions such as LLINs and samples after scale-up. 39 clones of the 215 
800bp fragment upstream of CYP6P9a were obtained and sequenced from ‘pre-intervention’ 216 
mosquitoes from Mozambique and Malawi and 52 from ‘post-intervention’ samples of both 217 
countries. Strikingly this portion was highly polymorphic pre-intervention with many 218 
segregating sites (61 and 25 in Malawi and Mozambique, respectively) and haplotypes (19 and 219 
12, a total of 30 for both) and high nucleotide diversity (=0.027 and 0.012) (Table S5; Fig. 220 
S5B). By contrast, the post-intervention samples exhibited very low diversity as revealed by all 221 
indexes with S of 4 and 3, haplotypes number of 2 and 4 with extremely low nucleotide diversity 222 
(=0.00066 and 0.0008), respectively in Malawi and Mozambique. The difference is reflected 223 
on the Maximum Likelihood (ML) phylogenetic tree showing that mosquito samples of pre-224 
intervention not only cluster together but are more diverse with several haplotypes (Fig. 4A). 225 
In contrast the post-intervention samples cluster noticeably away from the pre-intervention with 226 
drastically reduced haplotype number. A haplotype network confirmed that the major haplotype 227 
associated with resistance and now nearly fixed in all southern African populations was present 228 
also in the pre-intervention sample but at a much lower frequency of only 4/39 (19.23%) 229 
contrary to 44/52 (84.6%) in post intervention with other post haplotypes only 1 or 2 mutational 230 
steps away from the predominant one (Fig. 4B). The pre-intervention haplotypes were 231 
polymorphic and separated with high mutational steps whereas the post-intervention samples 232 
showed a marked reduced diversity (Fig. 4B). A detailed analysis of the polymorphisms 233 
between pre- and post-intervention samples, revealed that the AA insertion now common in 234 
southern populations as well as the CCAAT box was also present in pre-intervention samples 235 
but only at a very low frequency (7/24 in Malawi and 0/15 in Mozambique) whereas both AA 236 
and CCAAT box are now fixed in all the post-intervention samples (52/52). Furthermore, a 237 
second Nrf2:MafK binding site is found only in post-intervention samples and linked with both 238 
the AA insertion and the CCAAT box. These major modifications show that scale up of 239 
insecticide-treated nets is very likely the major factor that has driven this evolution in An. 240 
funestus populations in southern Africa. 241 
Detection of a molecular marker associated with pyrethroid resistance gene over-242 
expression  243 
Having confirmed that genomic changes upstream of CYP6P9a are associated with 244 
pyrethroid resistance, we next searched for the mutations responsible for the over-expression 245 
of CYP6P9a in resistant mosquitoes. We used luciferase assay to assess the role of 246 
polymorphisms found in the 800bp upstream of the translation start site (including the 5’ UTR). 247 
The 800bp upstream of the CYP6P9a translation start site in both FUMOZ and FANG was 248 
successfully cloned and sequenced. To narrow down the region containing the regulatory 249 
motifs, four different sized fragments of the 800, 500, 300 and 150 bp immediately upstream 250 
of the translation start codon were cloned upstream of a reporter gene in a pGL3 vector. These 251 
constructs were used in luciferase reporter gene assays that demonstrated that, while 800 bp 252 
inserts from both strains drove reporter gene expression, expression driven by the FUMOZ 253 
insert was 3 times higher than that from FANG (Fig. S6A), supporting that this region plays a 254 
role in the differential expression of CYP6P9a between resistant and susceptible mosquitoes. 255 
Progressive deletion of the 800-bp pGL3-FZ-CYP6P9a was performed to identify the major 256 
regulatory elements. The first deletion from 800 to 500bp did not impact the activity of the 257 
fragment. However, when the fragment was cut from 500 to 300bp removing the AA insert and 258 
the CCAAT box, it induced a 33% reduction of activity in the FUMOZ clone (P<0.001) (Fig. 259 
5A). Subsequent deletion from 300 to 150bp, removing the AA insert, the CCAAT box and the 260 
resistant specific CnCC/MafK binding site, led to a massive 89% reduction in activity 261 
(P<0.001). This shows that both the CCAAT box and the CnCC/MafK binding sites are key 262 
regulatory enhancer elements driving the over-expression of CYP6P9a. 263 
Design of a DNA-based diagnostic assay to detect CYP6P9a-mediated pyrethroid 264 
resistance 265 
To design a DNA-based diagnostic assay to detect CYP6P9a-mediated resistance, we 266 
screened the most active portion (500bp) for the presence of restriction site polymorphisms that 267 
could be used to design a simple PCR-RFLP. We found a restriction site for the TaqI enzyme 268 
(cut site 5'-TCGA-3’) spanning an A/G mutation located 18bp of the AA insertion (Fig. S6B) 269 
and completely tight with the CCAAT box and other regulatory elements on the resistance 270 
haplotype. The TaqI enzyme cuts the 450bp fragment from the ‘resistant’ haplotype into two 271 
fragments of 350bp and 100bp whereas ‘susceptible’ haplotypes remain uncut (Fig. 5B) 272 
allowing us to genotype the resistance allele in single mosquitoes. To validate the robustness 273 
of this PCR-RFLP to detect pyrethroid resistance, we used F8 progeny from a cross between 274 
highly resistant (FUMOZ) and highly susceptible (FANG) strains. The genotyping of 46 275 
mosquitoes highly resistant (alive after 180 minutes’ exposure) to permethrin (15) revealed 9 276 
RR, 35 RS and only 2 SS genotypes. By contrast, 42 highly susceptible mosquitoes (dead after 277 
30 minutes’ permethrin exposure) had 0 RR, 1 RS and 41 SS genotypes. Therefore, the odds 278 
ratio of the likelihood of surviving exposure to permethrin when homozygote for the resistant 279 
allele (RR) of the CYP6P9a gene (with the CCAAT box and CnCC/MafK binding sites) is 280 
highly elevated at 922 (P<0.0001) compared to the homozygous susceptible (SS) (Fig. 5C) 281 
demonstrating the reliability of this DNA-based metabolic resistance diagnostic assay. 282 
Geographical distribution of the resistant CYP6P9a allele across Africa: 283 
Genotyping the CYP6P9a_R allele across Africa revealed that it is nearly fixed in southern 284 
Africa and present at an intermediate frequency in Tanzania (East Africa) (55.7%). However, 285 
CYP6P9a_R is absent from Central/West Africa (Fig. 5D; Fig. S6C). In DR Congo, a 286 
geographical contrast was observed, with the CYP6P9a_R mutation present in the East of the 287 
country but absent from the West (Kinshasa). This pattern suggests a ‘new’ allele/haplotype 288 
that arose in southern Africa and is spreading northward. Regional differences in CYP6P9a_R 289 
distribution are like those reported for previous markers (6, 10). 290 
CYP6P9a_R reduces the effectiveness of insecticide-treated nets 291 
We next assessed the impact of CYP6P9a-based metabolic resistance on the 292 
effectiveness of LLINs using experimental hut trials. Mosquitoes from FANG/FUMOZ crosses 293 
(F4) were used after confirming their pyrethroid resistance status (Fig. S7A) and established 294 
that resistance was driven additively by CYP6P9a [OR = 693 and 131 respectively for RR vs 295 
SS and RR vs RS (P<0.001)] (Fig. 6A; Fig. S7B-D).  296 
Impact of CYP6P9a-mediated metabolic resistance on bed net efficacy using 297 
experimental huts: Females from the F4 generation of the FANG/FUMOZ strain were used in 298 
a release-recapture experiment in huts with PermaNet 2.0 (treated with deltamethrin), 299 
PermaNet 3.0 (deltamethrin plus PBO) and control nets (untreated). After 4 consecutive nights 300 
of release-recapture, analysis of the mosquitoes collected showed no significant induced 301 
exophily for both PermaNet 2.0 and PermaNet 3.0 compared to the control (P>0.05) (Table 1). 302 
The percentage of blood-fed females was significantly lower in both treated nets than in the 303 
untreated control, with PermaNet 3.0 showing a significantly lower number of blood-fed 304 
mosquitoes than PermaNet 2.0 (P<0.001) (Fig. 6B). This is reflected in the percentage of blood 305 
feeding inhibition which is significantly higher (P<0.0001) for PermaNet 3.0 (76.8%) than for 306 
PermaNet 2.0 (49.8%). Both treated nets provided greater personal protection than the untreated 307 
nets with, again, higher protection from PermaNet 3.0 (79.04%) than PermaNet 2.0 (61.9%) 308 
(Table 1). Analysis of mortality rates revealed very high mortality of the hybrid 309 
FANG/FUMOZ strain against PermaNet 3.0 (98.7%) compared to only 33.3% for PermaNet 310 
2.0 (P<0.001) (Fig. 6B). Very low mortality was observed in the control untreated net. 311 
Mosquitoes that had taken a blood meal through the nets also present a high mortality rate for 312 
PermaNet 3.0 (95.5%) but only a low rate for PermaNet 2.0 (40%).  313 
Assessing the role of CYP6P9a in the loss of efficacy of PermaNet 2.0: Genotyping 314 
of the CYP6P9a maker allowed us to assess the impact of P450-based metabolic resistance on 315 
the loss of efficacy of PermaNet 2.0.  Because most of the mosquitoes released in the PermaNet 316 
3.0 huts died, the impact of the CYP6P9a on the ability to survive exposure to LLIN was done 317 
only for PermaNet 2.0. To avoid confounding effects from blood feeding or net entry or 318 
exophily status, the distribution of the CYP6P9a genotypes was assessed first only among unfed 319 
mosquitoes collected in the room revealing a highly significant difference in the frequency of 320 
the three genotypes between the dead and alive mosquitoes (Chi2=375; P<0.0001) (Fig. 6B). 321 
Analysis of the correlation between each genotype and mortality revealed that CYP6P9a 322 
homozygous resistant mosquitoes (RR) were significantly more able to survive exposure to the 323 
PermaNet 2.0 than homozygous susceptible mosquitoes (odds ratio=34.9; CI=15.8-77.1; 324 
P<0.0001) (Table S6). Similarly, possessing the heterozygous (RS) genotype of CYP6P9a also 325 
confers a significant survival advantage than for the homozygous SS genotype (OR=19.9; 326 
CI=9.7-40.9; P<0.0001). Although a higher frequency of RR is observed in the alive 327 
mosquitoes than for the RS genotype, this difference was not significant (OR=1.75; CI=0.82-328 
3.7; P=0.26). Overall, a single CYP6P9a resistant allele (R) significantly confers the ability to 329 
survive than the susceptible allele (OR=6.25; CI=3.3-11.7; P<0.0001) (Fig. 6C). The same 330 
trend was observed when comparing the mortality in all samples although with at a lower degree 331 
(Table S6). The impact of the CYP6P9a resistance gene on the ability to blood feed was also 332 
assessed, revealing that the distribution of the three genotypes was significantly different 333 
between blood fed and unfed mosquitoes for both PermaNet 2.0 (Chi2=16.9; P<0.0001) and 334 
PermaNet 3.0 (Chi2=30.5; P<0.0001). Homozygous RR mosquitoes were significantly more 335 
likely to blood feed when exposed to PermaNet 3.0 than both susceptible SS (OR= 4.54; 336 
P<0.0001) and heterozygote RS individuals (OR= 2.6; P=0.0012) (Fig. 6C). A similar trend 337 
was observed for PermaNet 2.0, although not significant (Fig. S7E-F). This shows that despite 338 
the higher efficacy of PermaNet 3.0 compared to PermaNet 2.0, CYP6P9a_R could still 339 
increase the risk of malaria transmission. 340 
 341 
Discussion 342 
This study presents a comprehensive elucidation of the molecular genetic basis of 343 
metabolic resistance to pyrethroids in a major malaria vector detecting the first DNA-based 344 
resistance marker for P450-mediated metabolic resistance. A major outcome was the design of 345 
a field applicable diagnostic assay to detect and track the spread of this resistance across Africa 346 
and enabled us to establish the direct impact of metabolic resistance to pyrethroids on the 347 
efficacy of insecticide-treated nets in experimental huts. 348 
Overall, gene expression analyses underlined the importance of cytochrome P450 349 
monooxygenases in pyrethroid resistance as previously reported in other An. funestus 350 
populations (8, 15) and in other mosquito species (16-18). Important heterogeneities in gene 351 
expression were observed among populations from different geographical regions. Most 352 
notably, a cluster of CYP6 genes in the rp1 pyrethroid resistance QTL showed the most extreme 353 
differences in expression profiles among locations. Such differences show that the molecular 354 
basis of pyrethroid resistance varies across the continent as previously suggested for this species 355 
(19) and for other malaria vectors such as An. gambiae (7, 20). 356 
The association of the rp1 QTL locus with pyrethroid resistance is further supported by 357 
the detection of several adaptive evolutionary features across this locus, including i) signatures 358 
of selective sweep; ii) large structural variation with 6.5kb insert; and iii) cis-regulatory 359 
polymorphisms. The selective sweep detected around this region in southern Africa coincides 360 
with the high expression of the duplicated P450s CYP6P9a and CYP6P9b in Malawi supporting 361 
the key role in pyrethroid resistance of these genes previously shown to be efficient pyrethroid 362 
metabolizers (8). Selective sweeps associated with insecticide resistance have been reported 363 
recently in An. gambiae across Africa (21).  364 
The cis-regulatory changes detected here include binding sites for transcription factors 365 
such as CnCC/MAfK which has recently been shown to be involved in metabolic resistance in 366 
An. gambiae (22) and in other insects (23), supporting that cis-regulatory modifications are 367 
important drivers of metabolic resistance to insecticides. However, because cis-regulatory 368 
elements/enhancers are able to drive expression of genes from distant acting locations and can 369 
be upstream or downstream of the gene on which they function, future studies will help 370 
establish the role of the 6.5kb insert in the over-expression of CYP6P9a and CYP6P9b. The 371 
strong association of these regulatory variations with pyrethroid resistance provided an 372 
excellent opportunity to design a DNA-based diagnostic tool for metabolic resistance. This is 373 
the first diagnostic assay for P450-mediated resistance in malaria vectors which constitutes a 374 
major achievement in the field of resistance monitoring and surveillance. Indeed, while the first 375 
DNA-based diagnostic for target-site resistance (kdr) was established two decades ago (24), no 376 
such tool has been designed for metabolic resistance despite its greater risk to control 377 
interventions. Although sets of SNPs associated with pyrethroid resistance have been recently 378 
detected in the dengue vector Aedes aegypti, no causative markers were detected (25). Previous 379 
design of a DNA-based diagnostic tool were for a glutathione S-transferase gene (GSTe2) in 380 
An. funestus conferring pyrethroid/DDT resistance in West/Central Africa but using an amino 381 
acid change in the coding region of the gene, not the putative causative variant for over-382 
expression as done here for CYP6P9a (10). However, because this DNA-based assay mainly 383 
detects resistance in southern Africa and only applies to An. funestus, further efforts are needed 384 
to detect similar markers in other regions and other species to comprehensibly track P450-385 
mediated metabolic resistance Africa-wide.  386 
Strikingly, the CYP6P9a_R allele is present mainly in southern Africa, where it is nearly 387 
fixed, but completely absent from other regions. Such contrast between African populations of 388 
An. funestus has previously been observed, notably for the distribution of other resistance 389 
markers such as the L119F-GSTe2 (10) and the A296S-RDL conferring dieldrin resistance (26), 390 
which are present in West/Central and East Africa but completely absent from southern Africa. 391 
On the other hand, the N485I-ace-1 carbamate resistance allele is present only in southern 392 
Africa (6). Furthermore, patterns of FST-based genetic differentiation indicate a restriction of 393 
gene flow and high genetic divergence between southern Africa and other regions (11, 12). 394 
However, there seems to be a gradual increase of CYP6P9a_R frequency from south to north 395 
in southern Africa as seen in Malawi with 98% in the south (Chikwawa), 90% in the Centre 396 
(Salima) and 78 % in the north (Fulirwa). This correlates with previous observations that 397 
CYP6P9a over-expression was lower in the north and that the spread of this resistance likely 398 
originated from the far south and is spreading northwards across the species’ range (27). It will 399 
be important to monitor the spread of such alleles across the continent as there is the risk that 400 
super-resistant mosquitoes could be generated if, for instance, CYP6P9a-mediated pyrethroid 401 
resistance combines with the GSTe2-based DDT resistance seen in West/Central Africa. DR 402 
Congo will be particularly important to monitor as both resistance mechanisms are present in 403 
this country (28). 404 
Using the novel CYP6P9a_R assay, we successfully assessed for the first time the direct 405 
impact of metabolic resistance on the efficacy of insecticide-treated nets showing that P450-406 
mediated resistance was directly reducing the efficacy of insecticide-treated nets. This evidence 407 
further helps clarify the debate about whether pyrethroid resistance is directly impacting the 408 
efficacy of insecticide-treated nets (29) as it clearly highlights that pyrethroid resistance could 409 
jeopardize insecticide-based interventions. Interestingly, nets containing the insecticide 410 
synergist PBO, that inhibits the activity of cytochrome P450 enzymes, provided better efficacy 411 
than those with pyrethroid alone. However, despite the high mortality observed with the PBO-412 
based net, CYP6P9_R still increases the risk of malaria transmission with this net as resistant 413 
mosquitoes are still more likely than susceptible mosquitoes to bite and potentially transmit 414 
malaria, suggesting that malaria elimination efforts will be impeded unless the over-reliance on 415 
pyrethroids is addressed.  416 
Methods 417 
Study design 418 
The objective of this study was to detect key genetic variants conferring metabolic-mediated 419 
pyrethroid resistance in An. funestus and design a simple DNA-based assay to monitor such 420 
resistance in field populations and assess its impact on the effectiveness of insecticide-based 421 
control tools. Transcriptome profiling of An. funestus populations from four African regions 422 
[southern (Malawi), East (Uganda), West (Ghana), Central (Cameroon)] were analysed to 423 
detect key candidate resistance genes. Because metabolic resistance could also be conferred by 424 
point mutations in coding and cis/trans regulatory regions, we performed a comparative whole 425 
genome sequencing of field permethrin resistant and susceptible mosquitoes to screen for 426 
genomic resistance regions and polymorphisms. To comprehensively detect resistance loci, we 427 
also scanned the whole genome for pyrethroid resistance-related signatures of selective sweeps 428 
in southern Africa. As rp1 QTL was consistently associated with pyrethroid resistance, a fine-429 
scale analysis of this locus was performed to detect potential structural variants associated with 430 
resistance such as Indels and copy number variations. To detect cis-regulatory mutations 431 
controlling CYP6P9a/b-based pyrethroid resistance, we compared 800bp immediately 432 
upstream of CYP6P9a in resistant and susceptible mosquitoes. The role of insecticide-based 433 
interventions in the selection of this CYP6P9a cis-regulatory changes was assessed by 434 
sequencing mosquitoes collected before and after widespread insecticide-treated nets usage. To 435 
establish the specific mutations controlling CYP6P9a over-expression, a comparative luciferase 436 
assay between resistant and susceptible CYP6P9a promoter sequences was performed. To 437 
design a DNA-based diagnostic assay to detect CYP6P9a-mediated resistance, we screened the 438 
promoter for restriction sites to design a PCR-RFLP assay and use it to assess its distribution 439 
continent-wide. We next assessed the impact of CYP6P9a-based metabolic resistance on the 440 
effectiveness of LLINs using experimental hut trials. 441 
Collection and rearing of mosquitoes  442 
Two An. funestus laboratory colonies were utilised in the study.  The FANG colony is 443 
a fully insecticide susceptible colony derived from Angola (30). The FUMOZ colony is a multi-444 
insecticide resistant colony derived from southern Mozambique. Mosquitoes were collected 445 
from 4 primary locations across the continental range of An. funestus. Mosquitoes were 446 
collected in March 2014 from Obuasi (5°56′ N, 1°37′ W) in Ghana (31); in February 2015 from 447 
Mibellon (6°46′ N, 11°70′ E) in Cameroon; in March 2014 from Tororo (0°45’ N, 34°5’ E) in 448 
Uganda (32) and in January 2014 from Chikwawa (16°1’ S, 34°47’ E) in southern Malawi (33).    449 
Collected mosquitoes were kept until fully gravid and forced to lay eggs using the 450 
forced-egg laying method (34). All F0 females that laid eggs were morphologically identified 451 
as belonging to the An. funestus group according to a morphological key (35). Parents (F0) and 452 
egg batches were transported to the Liverpool School of Tropical Medicine under a DEFRA 453 
license (PATH/125/2012). Eggs were allowed to hatch in cups and mosquitoes reared to 454 
adulthood in the insectaries under conditions described previously (34). Insecticide resistance 455 
bioassays on these samples have been previously described (31-33). 456 
Transcription profiling of pyrethroid resistance using RNAseq 457 
Total RNA was extracted from pools of 10 female mosquitoes (alive after 1h permethrin 458 
exposure) using the Arcturus PicoPure RNA isolation kit (Life Technologies), according to the 459 
manufacturer’s instructions (Text S1).  Pools of libraries were sequenced, 8 per lane of the 460 
HiSeq 2500 (Illumina, San Diego, CA, USA) at 2x125 bp paired-end sequencing. Sequence 461 
library preparation and sequencing were done at the Centre for Genomic Research (CGR), 462 
University of Liverpool.  RNAseq data were analysed as described previously (36) (Text S1). 463 
This involved an initial processing, quality assessment of sequences and alignment to the 464 
reference sequence using the AfunF1.4 annotation. Differential gene expression analysis was 465 
performed using edgeR and StrandNGS program (Strand Life Sciences, version 3.0) (Text S1). 466 
Whole genome sequencing 467 
Genomic DNA was extracted from whole mosquitoes from F0 Malawi samples (2014), 468 
the pyrethroid resistant FUMOZ-R laboratory strain and the fully susceptible FANG strain 469 
using the DNAeasy kit (Qiagen, Hilden, Germany). For each sample, genomic DNA was 470 
extracted from individuals and pooled in equal amounts to form pools of DNA. These were 471 
sequenced on an Illumina HiSeq2500 (2x150bp paired-end). Initial processing and quality 472 
assessment of the sequence data was performed as for RNAseq data. Alignment of POOLseq 473 
R1/R2 read pairs and R0 reads to the reference sequence (the same as used for RNAseq 474 
alignment) as well as variant calling were performed as described previously (11).  475 
Polymorphism analysis of the promoter region of CYP6P9a  476 
To detect potential causative mutations conferring pyrethroid resistance in An. funestus, 477 
the polymorphism of the cis-regulatory region of the pyrethroid resistance gene CYP6P9a was 478 
analyzed. 479 
i-Detection of the causative mutations driving up-regulation of CYP6P9a:  An 800 480 
bp region upstream of the start codon of CYP6P9a was amplified and directly sequenced in 15 481 
field collected mosquitoes each from ten countries across different regions of Africa including 482 
southern (Mozambique, Malawi and Zambia), East (Uganda, Kenya and Tanzania), Central 483 
(DR Congo and Cameroon) and West (Benin and Ghana). Primers are listed in Table S7. 484 
Amplification and purification of PCR products was performed as previously described (11). 485 
Sequences were aligned using ClustalW (37) while haplotype reconstruction and polymorphism 486 
analysis were done using DnaSPv5.10 (38), MEGA (39) and TCS (40).  487 
ii) Investigation of the content of the CYP6P9a and CYP6P9b intergenic region: 488 
The entire 8.2kb intergenic region between both genes was amplified for the FUMOZ and 489 
FANG strains in 2 to 3 fragments using primers listed in Supplementary Table 22. PCR was 490 
performed using the Phusion polymerase following the manufacturer’s instructions. PCR 491 
products were purified and cloned into pJET1.2 plasmid. 492 
iii) Assessing the role of the scale up of insecticide-based intervention in the 493 
changes observed in the polymorphism of the promoter region of CYP6P9a: The same 494 
800bp region upstream of the CYP6P9a was amplified in mosquitoes collected before (pre-495 
intervention) the scale up of insecticide-treated nets and also after the scale up (post-496 
intervention) in Malawi (2002 and 2014) and Mozambique (2000 and 2016). The PCR products 497 
were cloned and sequenced and sequencing data analyzed as described above. 498 
Genotyping of the CYP6P9a resistance allele using PCR-RFLP 499 
A restriction site (5'-TCGA-3’) for the TaqI enzyme at the A/G mutation located 18bp 500 
of the AA insertion and completely tight with the CCAAT box on the resistance haplotype was 501 
used to design a PCR-RFLP assay to genotype the CYP6P9a_R allele. The RFLP6P9aF forward 502 
primer, 5’- TCCCGAAATACAGCCTTTCAG-3 and RFLP6P9aR 5’-503 
ATTGGTGCCATCGCTAGAAG-3’ reverse primers were used to amplify a partial CYP6P9a 504 
upstream region containing the restriction site. 10µl of the digestion mix made of 1µl of 505 
CutSmart buffer, 0.2µl of 2 units of TaqI restriction enzyme enzyme (New England Biolabs, 506 
Ipswich, MA, USA), 5µl of PCR product and 3.8µl of dH20 was incubated at 65°C for 2 hours. 507 
Restriction digest was separated on 2.0% agarose gel (Fig. 3D).  508 
Validation of the diagnostic test: To validate the robustness of the PCR-RFLP to 509 
detect the pyrethroid resistance in field population, F8 progeny from a cross between highly 510 
resistant (FUMOZ) and highly susceptible (FANG) strains previously used for QTL mapping 511 
(15) were genotyped and correlation with resistance phenotype established using Odd Ratio.  512 
Geographical distribution of resistant CYP6P9a allele across Africa: The 513 
geographical distribution of the resistant CYP6P9a allele across Africa was established by 514 
genotyping the CYP6P9a_R in 30-50 field-collected females of An. funestus from several 515 
countries in Africa using the PCR-RFLP.  516 
Luciferase reporter assay of CYP6P9a core promoter region 517 
The region immediately 5’ of CYP6P9a from both FUMOZ and FANG strains was 518 
amplified using primers 6P9a1F and 6P9R a/b. These primers gave an 817bp product for both 519 
FUMOZ and FANG which were cloned into pJET1.2 (Thermo Fischer Scientific) and 520 
sequenced. Primers were designed (Supplementary Table 22) to obtain constructs of 521 
progressive serial 5' deletions of the CYP6P9a promoter of 800bp, 500bp, 300bp and 150bp for 522 
the different primers. The primers incorporated either the SacI or MluI (for the FUMOZ) and 523 
KpnI or HindIII (for the FANG) to facilitate cloning in the pGL3 basic vector. Products were 524 
amplified with Phusion polymerase (Thermo Fischer Scientific) and cloned into pJET 1.2. The 525 
product was then excised from pJET1.2, ligated to pGL 3 basic (Promega) and sequenced. 526 
Plasmids were then extracted using Midiprep kit (Qiagen) to obtain high concentrations for the 527 
transfection. Dual luciferase assay was undertaken using An. gambiae cell line 4a-2 cell line 528 
(MRA-917 MR4, ATCC® Manassas Virginia). Approximately 5 x105 cells (600µl) was sub-529 
cultured from a T75 culture and seeded in each well of 24-well plate, 1 day prior to transfection 530 
and allowed to reach 60-70% conﬂuency. 531 
Transfection of the construct was carried out using the Qiagen effectene transfection 532 
reagent and the promoter activity measured using the Dual Luciferase Reporter Assay 533 
(promega, Madison, WI, USA). 600ng reporter constructs (CYP6P9a upstream sequences in 534 
pGL3-Basic), pGL3 without insert and LRIM promoter in pGL3 basic were co-transfected with 535 
1ng actin-renilla internal control in 60ml DNA condensation buffer, 4.8 ml enhancer and 6 ml 536 
effectene in triplicate. After 48h incubation at 25°C, the cells were washed with PBS and 537 
harvested in 100ml passive lysis buffer (Promega) and luciferase activity was measured on a 538 
luminometer (EG & GBert-hold, Wildbad, Germany). Renilla luciferase activity was used to 539 
normalize the construct luciferase activity. The values obtained after measuring the firefly 540 
(LAR II) luciferase activity, which represent the activity of the promoter, was divided by the 541 
corresponding Renilla luciferase activity values and the ratio used to compare different 542 
promoters.  543 
Evaluation of impact of CYP6P9a-based metabolic resistance on efficacy of 544 
insecticide-treated nets using experimental huts 545 
Study area and hut description: The study was performed in Mibellon (6°4'60" N and 546 
11°30'0" E), a village in the Adamawa region of Cameroon where we recently built 12 547 
experimental huts of concrete bricks, following the specific design for experimental huts from 548 
the West Africa region (41). 549 
Mosquito strains: The study was carried out with a hybrid strain generated from 550 
reciprocal crossing between the highly pyrethroid resistant strain FUMOZ-R (CYP6P9a_R) 551 
and the fully susceptible FANG strain (CYP6P9a_S) (42). After the initial F1 generation 552 
obtained from the reciprocal crosses of 50 males and 50 females of both strains, the hybrid 553 
strain was reared to F5 and F6 generations, which were used for the release in the huts. 554 
Susceptibility profile of the hybrid FANG/FUMOZ strain: WHO bioassays were 555 
carried out to assess the susceptibility profile of the two reciprocal hybrid strains for the 556 
pyrethroids (0.75% permethrin and 0.05% deltamethrin), DDT (4%) and the carbamate, 557 
bendiocarb (0.1%). The bioassays were performed according to WHO protocol (41). 558 
Study design: The following three treatments were compared in the experimental huts: 559 
(i) Untreated polyethylene net; (ii) PermaNet 2.0® (Deltamethrin incorporated into 560 
polyethylene net); (iii) PermaNet 3.0® (PBO + Deltamethrin incorporated into polyethylene 561 
net). To simulate a worn net, six holes of 4cm x 4cm were made on each net, according to WHO 562 
guidelines. The hybrid FANG/FUMOZ strain was released in each hut for 6 nights (80 563 
mosquitoes per hut).  564 
Ethical clearance: Three adult volunteers were recruited from the Mibellon village to 565 
sleep under the nets and collect mosquitoes in the morning. They were provided with a written 566 
consent form and given chemoprophylaxis during the trial. Ethical approval was obtained for 567 
the National Ethic Committee of the Ministry of the Health in Cameroon. 568 
Mosquito collection in huts: Early in the morning, mosquitoes were collected using 569 
glass tubes from: i) the room (the floor, walls and roof of the hut); ii) inside the net; iii) the exit 570 
traps (veranda). Each compartment had its own bag to avoid mixture between samples. 571 
Surviving mosquitoes were provided with sugar solution and held for 24 h in paper cups after 572 
which delayed mortality was also assessed. Samples were recorded in observation sheets as 573 
dead/blood fed, alive/blood fed, dead/unfed, and alive/unfed.  574 
The effect of each treatment was expressed relative to the control (untreated net) by 575 
assessing: i) induced exophily (the proportion of mosquitoes that exit early through the exit 576 
traps, treatment-induced exiting); ii) the mortality rate, an indicator of the potential mass killing 577 
effect of the LNs; iii) the blood feeding rate, an indicator of personal protection.  578 
Genotyping of the CYP6P9a metabolic resistance marker: To establish the impact 579 
of the CYP6P9a-mediated metabolic resistance to pyrethroids on the effectiveness of the 580 
insecticide-treated nets, the PCR-RFLP diagnostic assay was used to genotype a subset of each 581 
treatment including the dead, alive, blood feed, unfed, mosquitoes on the veranda, in the net 582 
and in the room. 583 
Statistical analysis:  584 
Genes differentially expressed in each country and between different countries 585 
(generated from Venn diagrams) were detected using DESeq normalization with fold change 586 
>2 and performing a multiple test correction using the method of Benjamini and Hochberg, at 587 
a false discovery rate of 5% (adjusted p value <0.05). Statistical significance of the Luciferase 588 
assays was assessed after an unpaired Student’s t-test with respective replicates between 589 
FUMOZ and FANG. Correlation between the CYP6P9a_R allele and pyrethroid resistance 590 
phenotype was established using Odd Ratio and Fisher’s exact test. The effect of both treated 591 
nets was established through a direct comparison to the untreated control net. The statistical 592 
significance of the difference was estimated by a logistic regression model using Wald statistic 593 
that follows a chi-squared distribution (with df=1). Odd Ratio and Fisher’s exact tests were 594 
used to assess the impact of CYP6P9a_R on the ability to survive and blood-feed after exposure 595 
to insecticide-treated nets. 596 
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Table 1: Experimental hut results with the FANG/FUMOZ strain 799 
 800 
 Untreated Nets PermaNet 2.0 PermaNet 3.0 
Total Mosquitoes 356 270 322 
% Exophily (CI) 11.8 (8.45-15.15) 16.7 (12.2-21.1) ns 15.8 (11.85-19.8) ns 
% Blood fed (CI) 29.5 (24.7-34.2) 
14.8 (10.6-19.05) § 6.8 (4.1-9.6) §ǂ 
% Blood feeding inhibition - 49.8§ 76.84§ǂ 
% Personal protection (Total 
blood fed) 
-(105) 61.9 (40) § 79.04 (22) §ǂ 
% Blood feeding Mortality (no 
dead blood fed)) 
1(1) 40.0 (16) § 95.5 (21) §ǂ 
% Mortality corrected (CI)  33.3 (27.7-38.9) § 98.7 (97.5-99.9) §ǂ 
For each comparison, estimates not sharing the same symbols (§ or ǂ) are statistically different 801 
at P<0.05 802 
 803 
 804 
Figure legends 805 
Figure 1: Transcriptional profiling: A) Venn-diagram showing number of differentially up-806 
regulated genes between different countries relative to FANG at FDR<0.01 and Fold-change 807 
>2. B) Volcano plots of differential gene expression between permethrin-exposed samples and 808 
the susceptible FANG highlighting differences in the expression of key resistance genes 809 
between countries. C) Heatmap showing the contrast in expression of major candidate 810 
detoxification genes between African regions. D) Fragments Per Kilobase of transcript per 811 
Million mapped reads (FPKM) of genes from rp1 pyrethroid resistance QTL highlighting 812 
differences between regions. E) Correlation between RNAseq and qRT-PCR. The data shown 813 
are mean + SEM (n = 3). 814 
  815 
Figure 2: Footprints of selective sweep associated with pyrethroid resistance. A) 816 
Contrasting polymorphism patterns between lab resistant (FUMOZ) and susceptible (FANG) 817 
strains and also between pre- (MWI-2002) and post-bednet intervention (MWI-2014) samples 818 
from Malawi (12). Data were aligned to 120kb rp1 BAC sequence (IGV screenshot). Each track 819 
shows the alignment depth (on a log scale for display purposes) respectively (coverage depth 820 
is capped at >100x).  Grey columns represent bases identical to the reference sequence while 821 
coloured columns indicate variant sites with a minor allele frequency >10%.  The genes of the 822 
P450 cluster are highlighted at the bottom. An increase read coverage is observed between 823 
CYP6P9a and CYP6P9b in pyrethroid resistant samples indicating the 6.5kb insert. B) Major 824 
signature of selective sweep detected around rp1 QTL pyrethroid resistance region across the 825 
2R chromosome in southern Africa but not in FANG susceptible strain after plotting Minor 826 
allele frequency (MAF).  827 
  828 
  829 
  830 
Figure 3: Genetic diversity of CYP6P9a 5’UTR region across Africa. A) Molecular Phylogenetic 831 
analysis of CYP6P9a 5’UTR region by Maximum Likelihood method; The evolutionary history of 832 
CYP6P9a promoter haplotypes across Africa was inferred by using the Maximum Likelihood method 833 
based on the Tamura 3-parameter model. B) Africa-wide TCS network for the CYP6P9a haplotypes 834 
showing four predominant regional haplotypes in southern Africa (STH10), West (Ghana, GHA11), 835 
Central (BEN/DRC21) and East/Central (EST/CNT 24). GHA, Ghana; CMR, Cameroon; MWI, 836 
Malawi; MOZ, Mozambique; ZMB, Zambia; TNZ, Tanzania; DRC, Democratic Republic of Congo; 837 
FNG, FANG. *, ancestral haplotype. Lines connecting haplotypes and each node represent a single 838 
mutation event (respective polymorphic positions are given on each branch). C) Neighbor-Joining 839 
phylogenetic tree of CYP6P9a-based genetic distance between ten African populations (NST estimates). 840 
  841 
Figure 4: Impact of scale up of bednet interventions on the genetic diversity of promoter 842 
region of CYP6P9a. A) Maximum Likelihood phylogenetic tree of CYP6P9a showing a cluster 843 
of highly diverse haplotypes pre-intervention but a nearly fixed haplotype post-intervention. 844 
Pink represents haplotypes before insecticide-treated nets whereas light blue are those post-845 
insecticide-treated nets. B) TCS haplotype network in Malawi and Mozambique Pre- and Post-846 
intervention revealing a major resistant haplotype post-intervention but a very diverse set of 847 
haplotypes before pre-insecticide-treated nets.  848 
 849 
Figure 5: CYP6P9a promoter analysis and design of a DNA-based diagnostic assay for 850 
P450-based metabolic pyrethroid resistance. A) Luciferase promoter assay (mean ± SD; 851 
n=6) of CYP6P9a 5' flanking region with progressive serial deletions to detect the causative 852 
variants. B) Agarose gel of TaqI PCR-RFLP of CYP6P9a, clearly distinguishing the three 853 
genotypes RR, RS and SS. C) Significant correlation (P<0.0001) between CYP6P9a resistance 854 
allele and permethrin resistance. D) Africa-wide distribution of the CYP6P9a resistant allele 855 
showing near fixation in southern Africa. 856 
 857 
Figure 6: Impact of the CYP6P9a-based metabolic resistance on bednet efficacy: A) 858 
CYP6P9a genotypes correlate with pyrethroid resistance in the hybrid strain of resistant 859 
(FUMOZ) and susceptible (FANG) strains supporting the use of this FANG/FUMOZ strain to 860 
assess the impact of CYP6P9a-mediated resistance on bednet efficacy. B) Blood feeding and 861 
mortality rates (mean ± SD; n=4) of FANG/FUMOZ strain after release-recapture in 862 
experimental huts with untreated (blue), PermaNet 2.0 (green) and PermaNet 3.0 (blue) nets. 863 
C) CYP6P9a genotype proportions in dead or alive mosquitoes after PermaNet 2.0 exposure 864 
showing that CYP6P9a_R significantly allows mosquitoes to survive bed net exposure 865 
(P<0.0001). D) Genotype proportions in blood-fed and unfed mosquitoes after PermaNet 3.0 866 
exposure showing that CYP6P9a_R allele increases the ability of resistant mosquitoes of taking 867 
a blood meal. 868 
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Material and Methods 880 
RNA extraction, sequence library preparation and sequencing 881 
Total RNA was extracted from pools of 10 female mosquitoes (alive after 1h permethrin exposure) using 882 
the Arcturus PicoPure RNA isolation kit (Life Technologies), according to the manufacturer’s instructions and 883 
including a DNase treatment step. For each pool, total RNA was rRNA-depleted with Ribo-Zero low input kit for 884 
Human/Mouse/Rat (Epicentre, Madison, WI, USA), using 100 ng of starting material. RNAseq libraries were 885 
prepared from Ribo-Zero mRNA-enriched material with the ScriptSeq v2 RNAseq library preparation kit 886 
(Epicentre), using 15 cycles of PCR amplification. Libraries were purified using Agencourt AMPure XP beads 887 
(Beckman and Coulter, Beverly, MA, USA). Each library was quantified using a Qubit fluorometer (Life 888 
Technologies, Carlsbad, CA, USA) and the size distribution assessed using the 2100 Bioanalyzer (Agilent, Santa 889 
Clara, CA, USA). 890 
Pools of libraries were sequenced, 8 per lane of the HiSeq 2500 (Illumina, San Diego, CA, USA) at 2x125 891 
bp paired-end sequencing with v4 chemistry. Sequence library preparation and sequencing were done at the Centre 892 
for Genomic Research (CGR), University of Liverpool.   893 
Analysis of RNAseq data 894 
Initial processing and quality assessment of the sequence data was performed as follows. Basecalling and 895 
de-multiplexing of indexed reads was performed by CASAVA version 1.8.2 (Illumina) to produce samples from 896 
the pooled sequence data, in fastq format. The raw fastq files were trimmed to remove Illumina adapter sequences 897 
using Cutadapt version 1.2.1 (1). Reads were further trimmed to remove low quality bases (with a window quality 898 
score <20), using Sickle version 1.200 (2).  899 
RNAseq R1/R2 read pairs were aligned to the reference sequence using the Subread aligner version 1.4.6 900 
(3). The reference annotation available (AfunF1.4) was further improved using BLAST2GO version 4.0.7 (4).  901 
Fragments mapped in the sense orientation to annotated An. funestus genes (automated predictions from 902 
gene set AfunF1.4, 2016-11-20, downloaded from VectorBase and annotated genes from the mitochondrial 903 
genome) were counted using featureCounts version 1.4.6 (5). Differential gene expression analysis was carried 904 
out using edgeR (6). Pairwise comparisons were carried out. Normalisation factors were calculated to correct for 905 
differences in total tag counts among samples, which may otherwise cause bias in differential gene expression 906 
analysis, using the “TMM” (Trimmed Mean M-values) method in edgeR (6) with default parameters. P-values 907 
associated with logFC were adjusted for multiple testing using the False Discovery Rate (FDR) approach (7). 908 
Significantly, differentially expressed genes were defined as those with an FDR-adjusted P-value <1% and >2-909 
fold absolute difference in expression level. Fragments per kilobase of gene sequence per million mapped reads 910 
(FPKM) was calculated using tag counts and the total CDS length. Gene ontology enrichment analysis was carried 911 
out on differentially expressed gene sets using BLAST2GO (4). 912 
The Strand NGS software (Strand Life Sciences, version 3.0) was also used to analyze the data following 913 
RNA alignment and RNA-seq analysis pipeline with standard parameters.  914 
 915 
Results 916 
RNAseq transcriptional profiling of mosquitoes from across Africa identifies candidate pyrethroid-917 
resistance associated genes 918 
The annotation gene set AfunF1.4 includes 13,506 protein coding gene annotations.  However, only 5,095 919 
of these were functionally annotated. To improve the functional annotation of the genome, we used BLAST2GO 920 
(4) to assign descriptions and gene ontologies using sequence similarity. This analysis assigned putative 921 
descriptions to 12,196 protein coding genes and gene ontology descriptions to 10,072.   922 
All read libraries were aligned to the reference genome. The quality metrics and the alignment parameters 923 
are presented in Table S1. Analysis with EdgeR and StrandNGS generated similar results. The number of 924 
differentially expressed genes between the four populations and the FANG susceptible strain or between 925 
populations is represented in the Venn diagram (Fig. 1A; Fig. S1A) whereas the expression profile is shown in the 926 
volcano plot for each country (Fig. 1B-E). 927 
Gene Ontology (GO) enrichment: After quality control and analyses (Table S1), GO enrichment was 928 
performed to assess the generic metabolic terms associated with resistance. Permethrin resistant mosquitoes in 929 
Malawi showed significant enrichment of gene ontologies associated with cytochrome P450 genes in genes over-930 
expressed relative to the fully susceptible FANG. These GO terms include heme binding, tetrapyrrole binding, 931 
oxidoreductase activity and iron ion binding (Fig. S2A). These GO terms among others are also enriched in the 932 
Ghana over-expressed gene set (Fig. S2B). In Uganda, more GO terms are enriched among the over-expressed 933 
genes but not directly associated with detoxification activities (Fig. S2C). 934 
 935 
Candidate resistance genes commonly up-regulated Africa-wide:  936 
To elucidate the continent-wide drivers of pyrethroid resistance in An. funestus, we first detected the sets 937 
of genes commonly over-expressed in all four regions. Cytochrome P450 genes were the most predominant 938 
detoxification genes on this list (Table S2). The two duplicated P450 genes CYP6P9a and CYP6P9b were the most 939 
abundantly expressed notably in Malawi with fold change (FC) of 60.5x and 23.9x respectively. Although these 940 
two genes are also up-regulated in other regions of East, West and central Africa, it is with a much-reduced fold 941 
change with FC of 2.1, 6.3 and 2.7 only respectively in Cameroon, Ghana and Uganda for CYP6P9a. This suggests 942 
that this gene is more specific to the southern region (Fig. 1B-D). Besides these two genes, other P450s commonly 943 
up-regulated had lower FKPM <1000. Among these, the CYP325A gene presented a marked increase in Central 944 
Africa with FC of 26.9 in Cameroon in contrast to other regions where FC<6 suggesting that the over-expression 945 
of this gene could be more specific of this region. Two glutathione S-transferases GSTe6 and GSTD3 were also 946 
commonly up-regulated in all four regions at similar FC between 2.6 and 4.9.  947 
Genes commonly up-regulated in three regions: Among the genes commonly expressed in three out 948 
of four regions, are two P450s. The duplicated CYP6P4a and CYP6P4b are highly over-expressed in Ghana with 949 
FC of 44.8 and 23.9 respectively but lower FC (<5.9) in Malawi and Uganda but not up-regulated in Cameroon. 950 
The other P450, CYP6P5, also located on the rp1 pyrethroid resistance QTL region is over-expressed in all regions 951 
but not in southern Africa (Fig. 1D). Other P450s differentially expressed have lower FC including CYP4C36 (not 952 
over-expressed in Uganda), CYP306A1 (not in Ghana), CYP315A1 (not in Malawi). Strikingly a set of GSTs from 953 
the epsilon class where up-regulated in all regions except East Africa including GSTe2 previously shown to confer 954 
DDT and pyrethroid resistance, which nevertheless exhibits higher FC in Cameroon and Ghana than Malawi 955 
(Table S2). These epsilon GSTs also include GSTe1, GSTe3 and GSTe5. The GSTD1 presented a high FPKM>10k 956 
in Malawi, Ghana and Uganda suggesting a role for this gene in these regions but not in Cameroon where it is not 957 
significantly over-expressed.  958 
Genes commonly up-regulated only in two regions: Analysis of the sets of genes up-regulated only in 959 
two regions revealed the presence of key P450s. Among these are CYP6M7 and CYP9J11 both with abundant 960 
reads counts, up-regulated only in southern and West Africa with FC around 2 and 3. These genes have previously 961 
been shown to metabolise pyrethroids (8, 9). Another P450, CYP6N1 located on the rp2 QTL chromosome, is also 962 
up-regulated in southern and West Africa only. The CYP9K1 P450 gene is up-regulated in East and West Africa 963 
although with higher FC in East (FC5.2). Among the genes only up-regulated in West and Central Africa, are a 964 
carboxylesterase AFUN002514 with FC of 5.5 and 3.6 respectively in Cameroon and Ghana but also the 965 
glutathione S-transferase GSTe4. Among the list of genes only present in Central and Southern Africa are also a 966 
carboxylesterase (AFUN000422) and a GST, AFUN007291 (GSTt2). Other detoxification genes are up-regulated 967 
only in one regions and usually have a relatively low FC (Table S2). 968 
 969 
Quantitative RT-PCR: To validate the RNAseq transcription profile, the expression levels of fifteen 970 
detoxification genes was also assessed by qRT-PCR for both permethrin resistant (Fig. S3A) and unexposed (Fig. 971 
S3B) mosquitoes. These genes included 12 P450s differentially expressed across the different regions as well as 972 
one GST, one aldehyde oxidase and one carboxylesterase. Primers were previously published (8, 10). Firstly, 973 
control mosquitoes not exposed to insecticides also showed a strong correlation (R2=0.695; P=0.002 in Malawi) 974 
with permethrin resistant samples used for RNAseq (Fig. 1E) supporting a constitutive expression of these 975 
candidate resistance genes to confer resistance. Overall, a high and significant correlation was observed between 976 
qRT-PCR and RNAseq results for the 4 countries when compared to FANG (R2=0.85; P<0.001) (Fig. S3C). 977 
However, significant differences were observed for the expression of some genes such as the CYP6Z1 P450 which 978 
for qRT-PCR exhibited a high up-regulation in Malawi (FC 66) and Ghana (FC13.4) but not in RNAseq. This 979 
gene has previously also been shown to be over-expressed in southern Africa using microarray and qRT-PCR (11) 980 
suggesting that RNAseq could have missed or that the primers was not efficient with the susceptible FANG strain. 981 
Similarly, the aldehyde oxidase gene (AFUN000093) was significantly over-expressed with qRT-PCR in all 982 
regions except Cameroon but not with RNAseq. This could be due to the poor annotation of some of these genes 983 
in the current An. funestus genome with certain genes been mistakenly combined. 984 
 985 
Complex evolution of the gene cluster of the rp1 CYP6 genes associated with pyrethroid resistance 986 
Due to the strong evidence of selection at rp1 across southern Africa from RNAseq profiles, a detailed 987 
analysis of this major resistance locus was performed revealing that a large scale structural polymorphism may 988 
affect the evolution of the rp1 locus:  989 
Identification of a 6.5 kb insertion between CYP6P9a and CYP6P9b: Close inspection of the pooled-990 
template whole genome alignment to the 120 kb BAC sequence containing the CYP6 cluster showed two 991 
anomalous features in the 8.2 kb sequence between the paralogous genes CYP6P9a and CYP6P9b.  In some 992 
samples, the coverage depth was greater than for the surrounding sequence and some samples showed read pairs 993 
in the correct relative orientation (><) but with greater than expected insert sizes, indicative of a large indel: a 994 
“deletion” in the sequenced genome(s) or an “insertion” in the reference genome (Supplementary Figure 4A; Table 995 
4). The FUMOZ alignment contains reads that are left-clipped (the leftmost part of the read, as aligned to the 996 
reference, is clipped irrespective of the read’s orientation: so the 5’ end of a read aligned to the positive strand and 997 
the 3’ end of a read aligned to the negative strand) between BAC sequence positions 37409 and 37410 (37410 998 
being the leftmost base included in the insertion).  It also contains reads that are right-clipped between positions 999 
43954 and 43955. This defines a region of 6545 bp. The presence of only left-clipped reads on the left of the region 1000 
and right-clipped reads on the right of the region indicates two things in FUMOZ: (i) that the “insertion” form of 1001 
the indel is fixed in the FUMOZ sample (there is no evidence for presence of the “deletion” form), and (ii) that the 1002 
inserted sequence is homologous to part of a larger sequence found elsewhere in the genome (indicated by the 1003 
“clipped” parts of the reads). 1004 
In FANG the situation is more complicated. At the left end of the insertion there are reads left-clipped 1005 
between positions 37409 and 37410 (as for FUMOZ) but also some reads right-clipped slightly further left, 1006 
between positions 37404 and 37405.  At the right end of the insertion there are reads right-clipped between 1007 
positions 43954 and 43955 (as for FUMOZ) but also some reads left-clipped between the same positions.  In 1008 
addition, further to the right there are some reads right-clipped between positions 44053 and 44054 and some left-1009 
clipped between positions 44070 and 44071. Detailed inspection of the clipped reads showed that the reads right-1010 
clipped at 37404/37405 and left-clipped at 43954/43955 indicate the “deletion” form of the indel, as the clipped 1011 
parts of the reads from the left and right end of the insertion overlap each other (but also contain a short length of 1012 
DNA that does not match FUMOZ).  The clipping at 44053/44054 and 44070/44071 is due to a region of 35 bp in 1013 
FANG (TAA TAC CGG GAG ATA CAT GGA GCT CGT GTA AAA GA) that does not align with the FUMOZ 1014 
reference (ATA TGT CGG AGG TTT AT) at the same location.  Overall, FANG shows evidence of the “deletion” 1015 
form of the indel in addition to the presence of the large homologous sequence elsewhere in the genome.  This 1016 
makes simple inspection of the alignment misleading, as rather than a loss of coverage across the 6.5 kb indel, 1017 
coverage is seen due to reads originating from sequence elsewhere in the genome.   1018 
Identifying the presence or absence of the insertion in samples from different geographical 1019 
locations in Africa: To determine the geographical extent of the FUMOZ-like “insertion” haplotype, a PCR 1020 
amplification of the 8.2kb was performed with two possible fragments obtained; a 1.7kb in case of absence of the 1021 
6.5kb insert or the 8.2kb in presence of the insert. The results indicate that the 6.5 kb insertion between CYP6P9a 1022 
and CYP6P9b was present only in southern Africa population of Malawi, where it was nearly fixed (only a single 1023 
read in Malawi supported the deletion haplotype) (Supplementary Table 5). However, populations from other parts 1024 
of Africa showed no evidence of the insertion haplotype. Evidence that the insertion existed (albeit at low 1025 
frequency) in the early 2000s comes from its presence in the FUMOZ colony, which was colonized form the field 1026 
in Mozambique in 2000, and subsequently selected for insecticide resistance, which appears to have fixed the 1027 
insertion haplotype in colony. 1028 
Investigating the genomic origin of the 6.5kb insertion: To identify the genomic origin of the inserted 1029 
6.5 kb sequence, it was extracted from the BAC sequence and used to search the An. funestus FUMOZ AfunF1 1030 
reference genome assembly using BLASTn implemented in the VectorBase web resource. The results indicated 1031 
that the sequence occurred at two different locations in the genome, both of which were on scaffold KB669169. 1032 
KB669169 is 1,771,395 bp long and contains the CYP6 cluster between positions 1,340,840 (the 3’ end of 1033 
CYP6AA1) and 1,431,230 (the 5’ end of CYP6AD1).  The first location was from 1,378,027 to either 1,403,987 or 1034 
1,410,005.  This is the “inserted” location, between CYP6P9a and CYP6P9b. The two different right-hand 1035 
positions may be due to the poor quality of the assembly across the CYP6 cluster, with maybe gaps in the assembly 1036 
in this region, and the possible inclusion of the same sequence twice when the contigs should have been merged. 1037 
The second location was between 1,109,272 and 1,118,666, approximately 260 kb away from the CYP6 cluster 1038 
on the same scaffold (therefore, on the same chromosome). In addition, short (100 bp) sequences from the left and 1039 
right ends of the insertion were used to conduct BLASTn searches of AfunF1 and confirmed the results obtained 1040 
with the full-length insertion sequence. Finally, clipped sequences from immediately to the left and right of the 1041 
insertion were used to conduct BLASTn searches of AfunF1. The results (matches only adjacent to the 1042 
KB669169:1109272-1118666 region) confirmed that the “parent” sequence of the insertion between CYP6P9a 1043 
and CYP6P9b came from KB669169:1109272-1118666. This putative genomic “parent” sequence of the insert 1044 
contains no annotated protein coding genes but there is a large assembly gap in the region. The orthologous region 1045 
in the Anopheles gambiae genome is on chromosome arm 2R. The protein coding genes flanking the insertion 1046 
sequence, AFUN008344 and AFUN008346, are orthologous to AGAP002842 and AGAP002845, respectively.  1047 
An. gambiae has no annotated protein coding genes between AGAP002842 and AGAP002845, suggesting that 1048 
An. funestus may not have also. Three micro-RNAs annotated in both species are outside of the insertion sequence. 1049 
One of these (mir-317; AFUN015669) has its 5’ end approximately 130 bp away from the leftmost breakpoint of 1050 
the insertion. Despite the lack of annotated genes, the region is transcribed and shows a large transcribed region, 1051 
with some evidence of splicing, covering the three annotated micro-RNAs. Whether this transcript is processed to 1052 
form mature micro-RNAs is not known. 1053 
Detection of a molecular marker associated with pyrethroid resistance 1054 
i-Comparative analysis of the cis-regulatory region of CYP6P9a between susceptible and resistant 1055 
mosquitoes: To have a full view of the potential regulatory elements driving over-expression of CYP6P9a, we 1056 
amplified and sequenced the full 8.2kb intergenic region between CYP6P9a and CYP6P9b in individual resistant 1057 
(FUMOZ_R) and susceptible (FANG) mosquitoes. Amplifications revealed that while resistant mosquitoes have 1058 
the full 8.2 kb region, the susceptible ones only present a 1.7kb size for this intergenic region confirming the 1059 
insertion of a 6.5 kb fragment in resistant mosquitoes. This insertion is present in the lab resistant FUMOZ strain 1060 
(reference genome) as well as all southern Africa to near fixation (Malawi, Mozambique and Zambia). However, 1061 
mosquitoes from other parts of the continent were similar to the lab susceptible strain FANG. To understand why 1062 
such insertion occurred in resistant mosquitoes in southern Africa, we analyzed the composition of the 6.5kb 1063 
fragment which occur at 830bp from stop codon of CYP6P9b and at 905 from start codon of CYP6P9a. Using 1064 
GPminer (12), we detected, that it is full of transcription factor sites including an cpg island of 1.3kb and several 1065 
GATA sites. It also contains several TATA (35), CCAAT (12) and GC (11) sequences. Furthermore, this 6.5kb is 1066 
rich in over-represented (OR) oligonucleotides. Using the Alggen Promo program, to search for key transcription 1067 
factors associated with regulation of genes involved in xenobiotics detoxification, revealed an abundant number 1068 
of binding sites (51) for the Cap n Collar C (CnCC) and the Muscle aponeurosis fibromatosis (Maf) transcription 1069 
factors sites which are known xenobiotic sensors in insects. Other of these sensors were also detected in the 6.5 1070 
kb including 14 binding sites for Ahr:Arnt, 13 for SXR:PXR and also for HNF4. The richness of this 6.5kb in 1071 
regulatory factors suggests that this insertion contributes to increase regulation of CYP6P9a gene. Noticeably this 1072 
6.5kb contains a microsatellite (FUNR) (13), 388bp in size and located between 6082bp and 6482bp, only 80bp 1073 
from the 5’UTR of CYP6P9a. Previous genotyping of this marker Africa-wide revealed significant differences 1074 
associated with pyrethroid resistance profile. This FUNR is not present within the 1.7kb intergenic region between 1075 
CYP6P9a and CYP6P9b for the FANG susceptible strain or before bednets distribution. It has been shown that 1076 
microsatellite loci are involved in upregulation of P450 to confer insecticide resistance in other insects such as 1077 
Aphid (14). It has also been shown in Yeast that polymorphic tandem repeats in the promoter regions can activate 1078 
gene expression by impacting local chromatin structure to act as “evolutionary tuning knobs” to drive rapid 1079 
evolution of gene expression such in a case of insecticide resistance selection. However, the FUNR has been 1080 
detected in mosquitoes lacking this 6.5kb across Africa suggesting that for those populations’ portions of this 6.5 1081 
kb are located in other regions of the genome close to 2R chromosome. There is also the possibility of the 6.5kb 1082 
in resistant mosquitoes is causing a chromatin remodeling thereby promoting the access of the transcription factors 1083 
to the promoter (15).  1084 
Geographical distribution of the resistant CYP6P9a allele across Africa: To establish the 1085 
geographical distribution of the resistant CYP6P9a allele, field populations of An. funestus collected from several 1086 
countries in Africa were genotyped using PCR-RFLP. This revealed that the CYP6P9a-R allele is mainly present 1087 
in southern Africa where it is close to fixation in Mozambique, Malawi and Zambia. The allele is also present in 1088 
Tanzania in East Africa, although at lower frequency than in southern Africa (55.7%). However, in correlation 1089 
with sequencing data, the CYP6P9a-R is completely absent in Central and West Africa (Fig. 5D; Fig. S6C). This 1090 
total absence of CYP6P9a-R in West-Central Africa supports the restriction to gene flow we are observing for this 1091 
species maybe because of the Rift Valley. In DR Congo, a contrast was observed between East and West as the 1092 
CYP6P9a-R mutation is present in East but absent in the West (Kinshasa). It is important to monitor the spread of 1093 
this marker across DRC to assess the speed and direction of spread of this resistance allele.  1094 
CYP6P9a_R reduces the effectiveness of insecticide-treated bed nets 1095 
To assess the impact of the CYP6P9a-R haplotype on the effectiveness of LLINs, we opted to use lab 1096 
strains as this mutation is nearly fixed in the field in southern Africa. We crossed the highly resistant laboratory 1097 
strain FUMOZ-R (where CYP6P9a_R is fixed) with the fully susceptible laboratory strain FANG (where 1098 
CYP6P9a_R is completely absent). Using reciprocal crosses between the two strains we generated a hybrid strain 1099 
at the F4 generation that we used for semi-field studies in experimental huts. 1100 
 Susceptibility profiles of the FANG/FUMOZ and FANG/FUMOZ strains: The bioassays performed 1101 
with the reciprocal FANG/FUMOZ strains revealed that both hybrid strains were resistant to pyrethroids and 1102 
carbamates and moderately resistant to DDT (93% mortality) (Fig. S7A). As expected, the level of resistance was 1103 
lower than in the fully resistant strain FUMOZ_R, with a mortality rate of 76.1-80.7% when exposed to permethrin. 1104 
However, a significant difference was observed for deltamethrin with a higher mortality rate recorded for the strain 1105 
generated from crossing females FUMOZ_R to males FANG (48.5%) than in the strain from females FANG and 1106 
males FUMOZ_R (77.3%). This difference could indicate the role of some candidate genes in the X chromosome 1107 
for deltamethrin resistance (CYP9K1, for instance). Resistance pattern was similar for the carbamate bendiocarb 1108 
in both reciprocal strains. 1109 
Validating the role of CYP6P9a-R in pyrethroid resistance in the hybrid FANG/FUMOZ strains: 1110 
Before any field studies with the hybrid FANG/FUMOZ strains, the role of the CYP6P9a_R allele in the observed 1111 
pyrethroid resistance was confirmed. WHO bioassays showed a mortality of 39.0% and 42.3% after 30 minutes’ 1112 
exposure and mortality rates of 81.3% and 86.3% after 90 minutes’ exposure, respectively to permethrin and 1113 
deltamethrin (Fig. S7B).  The odds ratio of surviving exposure to permethrin when homozygous for the resistant 1114 
CYP6P9a_R allele (RR) was high at 693 (CI 88-5421; P<0.0001) compared to the homozygous susceptible (SS) 1115 
(Fig. S7C-D). The OR was 131 (CI 27-978; P<0.0001) when comparing RR to RS indicating that the resistance 1116 
conferred by CYP6P9a is additive. 1117 
 1118 
  1119 
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Fig. S1. Differential gene expression between four permethrin-exposed samples and FANG. A) Venn-1174 
diagram showing number of differentially downregulated genes between different countries relative to FANG at 1175 
FDR<0.05 and Fold-change > 2. B) Volcano plot of the expression of between CMR and FANG susceptible strain. 1176 
The X-axis shows log2 fold-change (positive values are up-regulated relative to FANG).  The Y-axis shows -log10 1177 
transformed P values (adjusted for multiple testing; values greater than 40 were displayed as 40). The horizontal 1178 
dashed line marks P=1% and the vertical dashed lines indicate two-fold expression difference among conditions. 1179 
Red points indicate genes annotated as cytochrome P450s and green points indicate GST and blue points represent 1180 
carboxylesterases. C) is for Malawi, D) for Ghana and E) is for Uganda. 1181 
 1182 
Fig. S2: Gene ontology enrichment of upregulated genes using BLAST2GO: A) Malawi, B) Uganda, C) 1183 
Ghana. The test set represents the transcripts up-regulated while the reference set is made of the entire An. funestus 1184 
transcript set (Afun1.4). Significance of the enrichment was assessed using a Benjamini and Hochberg multiple 1185 
testing correction (P< 0.05). No significant terms detected for Cameroon at FDR of 0.1186 
 1187 
 1188 
 1189 
Fig. S3: qRT-PCR validation of the expression profile of the main detoxification genes differentially 1190 
expressed between resistant and susceptible pyrethroid samples with RNAseq. A) qRT-PCR expression 1191 
profile between R-S; B) qRT-PCR expression profile between C-S; C)Correlation between qRT-PCR  of R_S and 1192 
C-S. The data shown are mean + SD (n = 3).1193 
 1194 
Fig. S4: Insertion of a 6.5kb intergenic fragment between CYP6P9a and CYP6P9b in southern African 1195 
mosquitoes. A) Screenshot from the integrative genomics viewer (IGV), showing coverage depth and aligned 1196 
reads for FUMOZ (upper) and FANG (lower) pooled template whole genome sequence alignments. The coverage 1197 
depth plots show deeper coverage in this region in FUMOZ but not in FANG. The FANG alignment contains read 1198 
pairs with unusually long insert sizes, indicated in red in the lower panel (thick lines represent reads, read pairs 1199 
are linked by thin lines). B) Schematic representation of the process of insertion from a one region of the genome 1200 
to another, generating 2 homologous sequences in different parts of the genome. 1201 
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 1203 
Fig. S5: Genetic diversity patterns of an 800bp cis-regulatory genomic fragment of CYP6P9a Africa-wide 1204 
and before and after LLIN scale up. (A) Polymorphic sites and haplotypes across Africa. Haplotypes are labeled 1205 
with prefixes from the country where they are predominant. CMR, Cameroon, GHA is Ghana, BEN is Benin, TNZ 1206 
is Tanzania, DRC is Democratic Republic of Congo, MOZ is Mozambique, STH is Southern Africa, MWI is 1207 
Malawi, ZMB is Zambia, EST/CNT is East/Central Africa. B) Polymorphic sites and haplotypes before and after 1208 
scale up of LLINs in Mozambique and Malawi. Haplotypes are labeled with prefixes from the sample where they 1209 
are predominant. PreMWI is for Pre-intervention Malawi, PreMoz is Pre-intervention Mozambique; PostMWI is 1210 
Post-intervention Malawi; PostMoz is for Post-Intervention Mozambique. 1211 
 1212 
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 1213 
Fig. S6: Design of a DNA-based diagnostic assay to detect and track pyrethroid resistance across Africa. A) 1214 
Comparative luciferase assay between promoter fragment from the highly resistant FUMOZ and highly susceptible 1215 
(FANG) lab strains with progressive serial deletions of CYP6P9a 5' flanking region to detect the causative variants. 1216 
Bars represent the mean ± S.D. of four independent transfections of three replicates (n = 6).  A significant 1217 
difference between promoter constructs (p < 0.001, Tukeys’s t-test) is indicated by an asterisk. B) Schematic 1218 
alignment of sequences across Africa showing fixed differences associated with pyrethroid resistance including 1219 
the AA insert only found in resistant mosquitoes and the A/G variant tightly linked to the resistant haplotype and 1220 
generating a restriction site for the TaqI restriction enzyme. C) Frequency of the CYP6P9a_R allele across Africa 1221 
showing that it is only present in southern Africa where it is close to fixation but also in East Africa at moderate 1222 
level. However, it is completely absent in Central and West Africa.1223 
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Fig. S7: Impact of the CYP6P9a-based metabolic resistance on the efficacy of bed nets using semi-field experimental 
hut trials: A) Susceptibility profile of the hybrid strain generated from crossing the highly resistant (FUMOZ) and highly 
susceptible (FANG) strains. Perm is permethrin, Delt is deltamethrin and Ben is bendiocarb. B) Mortality rates of the 
FANG/FUMOZ hybrid strain at two time-points exposure to validate the correlation between CYP6P9a and resistance 
phenotypes to pyrethroids. C) Distribution of the CYP6P9a genotypes according to resistance phenotypes. D) Strong 
correlation between CYP6P9a alleles and survival to PermaNet 2.0 exposure in experimental huts. E) CYP6P9a-R allele 
increases the ability of resistant mosquitoes of taking a blood meal in contrast to susceptible ones when exposed to PermaNet 
2.0 but not for the untreated nets F). 
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Table S1.  Descriptive statistics of RNAseq sequence read data and alignments for different samples 
 
Sample ID 
Untrimmed 
reads 
Trimmed 
reads 
R1/R2 pairs 1 R0 reads (%) 2 
Reads to align 
(R1+R2) 
Aligned reads (%) 3 Aligned R1 (%) 4 Aligned R2 (%) 4 Aligned in pair (%) 4 
Properly paired (%) 
4,5 
FNG-UNX-000A-01 61,161,962 60,814,246 30,239,816 334,614 (0.55%) 60,479,632 34,529,287 (57%) 17,175,707 (50%) 17,353,580 (50%) 32,558,814 (94%) 30,926,294 (90%) 
FNG-UNX-000A-02 44,384,316 43,991,605 21,866,954 257,697 (0.59%) 43,733,908 38,784,564 (89%) 19,455,342 (50%) 19,329,222 (50%) 37,497,734 (97%) 35,662,300 (92%) 
FNG-UNX-000A-03 55,329,478 55,003,414 27,346,953 309,508 (0.56%) 54,693,906 41,539,393 (76%) 20,695,859 (50%) 20,843,534 (50%) 39,451,822 (95%) 37,642,472 (91%) 
FNG-UNX-000A-07 61,708,692 60,522,621 30,147,658 227,305 (0.38%) 60,295,316 52,613,292 (87%) 26,304,258 (50%) 26,309,034 (50%) 51,355,756 (98%) 49,077,570 (93%) 
GHA-PER-060A-01 56,393,812 56,004,973 27,858,160 288,653 (0.52%) 55,716,320 47,383,161 (85%) 23,661,891 (50%) 23,721,270 (50%) 45,701,704 (96%) 43,711,894 (92%) 
GHA-PER-060A-02 56,146,206 55,778,128 27,745,363 287,402 (0.52%) 55,490,726 47,385,531 (85%) 23,689,592 (50%) 23,695,939 (50%) 45,668,698 (96%) 43,627,620 (92%) 
GHA-PER-060A-03 46,339,060 45,931,585 22,853,504 224,577 (0.49%) 45,707,008 35,745,010 (78%) 17,841,177 (50%) 17,903,833 (50%) 34,393,520 (96%) 32,935,172 (92%) 
CMR-PER-060A-01 45,564,004 45,336,332 22,563,410 209,512 (0.46%) 45,126,820 29,760,118 (66%) 14,809,654 (50%) 14,950,464 (50%) 28,136,026 (95%) 26,881,776 (90%) 
CMR-PER-060A-02 49,616,994 49,369,073 24,565,403 238,267 (0.48%) 49,130,806 36,825,328 (75%) 18,551,507 (50%) 18,273,821 (50%) 34,658,598 (94%) 32,960,464 (90%) 
CMR-PER-060A-03 56,448,220 55,238,405 27,521,162 196,081 (0.35%) 55,042,324 44,353,985 (81%) 22,394,524 (50%) 21,959,461 (50%) 42,605,426 (96%) 40,679,444 (92%) 
UGA-PER-060A-02 63,577,506 62,233,533 30,965,317 302,899 (0.49%) 61,930,634 49,080,456 (79%) 24,430,318 (50%) 24,650,138 (50%) 47,225,124 (96%) 45,294,140 (92%) 
UGA-PER-060A-03 74,281,024 72,571,899 36,050,602 470,695 (0.65%) 72,101,204 58,908,769 (82%) 29,401,087 (50%) 29,507,682 (50%) 56,385,738 (96%) 53,742,224 (91%) 
UGA-PER-060A-04 57,574,274 55,614,929 27,652,993 308,943 (0.56%) 55,305,986 43,887,550 (79%) 21,868,261 (50%) 22,019,289 (50%) 42,252,224 (96%) 40,393,696 (92%) 
MWI-PER-060A-06 72,542,372 72,016,218 35,777,777 460,664 (0.64%) 71,555,554 62,665,469 (88%) 31,430,727 (50%) 31,234,742 (50%) 60,517,686 (97%) 57,445,876 (92%) 
MWI-PER-060A-07 65,422,634 64,501,521 32,092,002 317,517 (0.49%) 64,184,004 56,244,764 (88%) 28,121,863 (50%) 28,122,901 (50%) 54,471,126 (97%) 52,005,820 (92%) 
1 Forward (R1) and reverse (R2) read pairs after trimming. 
2 Reads unpaired after trimming (% of total trimmed reads). 
3 % of reads to align. 
4 % of aligned reads. 
5 Properly paired means both read and its mate are mapped to opposing strands of the reference sequence, with 3’ ends innermost and 5’ ends within the allowed distance from each other (50-600 
bp).   
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Table S2: Detoxification-associated genes differentially expressed between the four pyrethroid resistant populations and the FANG susceptible strain 
 
Gene ID CMR GHA MWI UGA Description FG_S CMR GHA MAL UG 
AFUN010543 6.6 5.4 30.7 48.9 CCChain Structural Basis  0.28 0.98 2.8 7.1 8.9 
AFUN011806 4.2 2.1 13.2 6 chymotrypsin-like elastase family member 2A 0.17 0.65 0.4 3.3 1.2 
AFUN001444 14 6.2 4.4 3.2 chymotrypsin-like elastase family member 2A 4.5 56.8 31.5 28.9 16.3 
AFUN015830  2.4 2.6 3.9 2.2 Cytochrome P450, CYP325C 1.43 3.1 4.2 8.15 3.5 
AFUN015966  26.9 6 5.1 2.2 Cytochrome P450, CYP325A 0.74 17.4 4.8 5.2 1.8 
AFUN015894  3.1 2.3 7.5 3.7 Cytochrome P450, CYP4H26 0.3 0.9 0.85 3.6 1.4 
AFUN015792  2.1 6.3 60.5 2.7 Cytochrome P450, CYP6P9a 14.9 28.7 106.2 1355 45.6 
AFUN015889  4.4 6.9 23.9 7 Cytochrome P450, CYP6P9b 11.5 45.3 88.8 401.7 92.2 
AFUN015777  2.6 2.3 5.3 3.5 Cytochrome P450, CYP4C26 0.5 1.1 1.2 3.6 1.9 
AFUN015839  2.6 4.9 3.3 3 glutathione S-transferase, GSTD3 25.3 60.2 137.8 122.5 87.1 
AFUN016008  4.8 3.5 4.1 3.4 glutathione S-transferase, GSTE6 8.3 36.3 32.7 50.2 32.3 
AFUN004582 2.8 3.7 2.8 3.1 methyltransferase 2-A 0.7 1.8 2.8 2.8 2.4 
AFUN010812 4.9 2.9 9.6 3.1 General odorant-binding 45  0.4 1.2 0.9 4 1 
AFUN015887 2.6 2.3 2.2 2.5 Gustatory receptor 68a 7.5 17.4 19 23.9 21.8 
AFUN006831 3.6 2.2 3.7 4.4 General odorant-binding  0.4 0.8 0.6 1.3 1.2 
AFUN007097 2.8 8.2 4.6 4 cuticular_protein_RR 0.5 0.9 3.1 2.3 1.6 
AFUN005949 3.3 4.6 6.2 2.7 General odorant-binding 70  0.3 1 1.7 3 1.1 
AFUN004398 5.5 4.4 7.5 7.5 cuticular_protein_TWDL_family_(TWDL12) 0.7 1.1 1 2.3 1.8 
AFUN015818 6 3.6 11.8 4.1 Gustatory receptor for sugar taste 64b 0.4 1.1 0.8 3.5 0.9 
AFUN001299 3.5 3 2.6 3.7 NTF2-related export 2 6.9 21.5 23.4 26.5 29 
AFUN003480 2.4 2.7 3.7 2.7 serine protease 27-like 0.9 2 2.8 5 2.9 
AFUN010184 2.2 2.4 2 3.3 transcription factor GATA-3-like isoform X1  1.3 2.6 3.5 3.9 5 
AFUN007410 2.9 2.5 2.9 2.1 transmembrane protease serine 9-like 110.5 288.2 304 461.2 269.1 
AFUN007052 5.1 3.5 6 4.2 zinc finger 345-like isoform X1  1.1 1.8 1.5 3.3 1.8 
AFUN009311 2.3 2.3 2.4 2.3 zinc finger 391-like isoform X1  11.5 23.4 29.1 40.9 30.6 
AFUN010612 3.2 3 2.4 3.9 zinc finger 883-like isoform X2  1.7 4.9 5.7 6.1 7.8 
AFUN015890  44.8 5.9 2.1 Cytochrome P450, CYP6P4 2.3 3.6 114.2 19.7 5.5 
AFUN015891  23.9 3.7 2.7 cytochrome P450 CYP6P4-like 17.1 16.2 456.2 91.8 52.1 
AFUN016010   2.2 2 2.2 glutathione S-transferase, GSTD1 117.8 186.4 292 348.5 297.9 
AFUN000474 3.2  4.7 2.1 Gustatory receptor for sugar taste 43a 1.5 4.2 2.7 9.8 3.6 
AFUN000064 3.1  4.7 3.1 Cuticular Protein as AGAP010105-PA  0.7 2.1 1.6 5 2.7 
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AFUN010577 2.1  2.9 2.2 chymotrypsin-like elastase family member 2A 1.5 2.9 2.7 6.5 3.8 
AFUN006858 2.3  2.1 2.1 cytochrome P450 CYP306A1 8.2 17.4 17.8 24.9 19.8 
AFUN006563 2.7   3.9 3.3 Cuticular protein 0.4 0.11 0.078 0.26 0.18 
AFUN015888 6.3 5.8  4.1 Cytochrome P450, CYP6P5 6.3 36.2 41.1 8.5 29.6 
AFUN005715 2.2 2.3  2.3 Cytochrome P450, CYP315A1 10 19.8 25.5 28.3 26.7 
AFUN003202 2.2 2.1  2.1 nucleoporin Nup43 6.8 13.7 15.8 18.8 16.2 
AFUN006467 2.2 2.7  3.2 zinc finger 391-like isoform X1  7.2 14.5 21.4 17.9 26.9 
AFUN002969 2.6 2   2.4 zinc transporter ZIP10-like 10.6 24.8 24 22.9 29.3 
AFUN006135 2.2 2.9 2.6  Cytochrome P450, CYP4C36 8.8 17.5 29 33.3 14.5 
AFUN015808 2.5 3.3 2.3  glutathione S-transferase GSTE3 63.9 143.7 238.6 210.8 124 
AFUN015807 3.5 3.7 2.8  glutathione S-transferase GSTE1 5.2 16.5 21.7 20.9 9.3 
AFUN015809 5.9 8.3 2.3  glutathione S-transferase GSTE2 42.7 227 398.4 143.4 78.2 
AFUN015811 3 2.3 2.2  glutathione S-transferase GSTE5 28.3 76.9 73 89.4 49.4 
AFUN011266 3.1 2.7 4.9  UDP-glucuronosyltransferase 2.3 6.5 6.9 16.3 4.3 
AFUN015817 3.8 2.3 7.2  Gustatory receptor for sugar taste 64e 0.4 0.7 0.5 2.1 0.4 
AFUN000622 2.5 2.1 2.9  solute carrier family 23 member 2 7.2 16.2 16.7 30.1 12 
AFUN006863 2.1 2.1 2  zinc finger 345-like isoform X4 6.7 12.6 15.6 20 13.4 
AFUN000799 2.2 2 2.3   zinc finger CCHC-type  12.7 25.7 28.7 43.4 27 
AFUN015907   2.2 2.4 gastrula zinc finger -like isoform X1  8.4 14.9 18.6 26.7 23.6 
AFUN010481   4.4 3.1 Cuticular protein 0.11 0.3 0.06 0.53 0.3 
AFUN010539   2.3 2 cuticular_protein_RR-2_family_(CPR143) 2.1 3.2 4.6 7 4.9 
AFUN004166   2.5 3.1  gustatory receptor 28b 2.8 4.8 5.8 10.3 10 
AFUN008855   3.9 2.8 nuclear receptor subfamily 2 group C  0.9 0.5 0.8 4.8 2.7 
AFUN005273     2 2.6 zinc finger 883-like isoform X2  3.7 5.1 6.4 11 11 
AFUN001382  2.7 2.4  Cytochrome P450, CYP9J11 69.5 87.3 206.1 241.7 144 
AFUN001383  2.4 3.1  Cytochrome P450, CYP9J11 20.5 23.5 54.2 93 36.4 
AFUN015795  2.2 2.2  Cytochrome P450, CYP6M7 118.7 119.1 297.8 372 150.8 
AFUN015767  3 2.9  glutathione S-transferase, GSTD11 1.8 2.3 6 7.6 2.2 
AFUN012021  2.4 5.9  Cuticular potein 0.16 0.22 0.33 1.1 0.17 
AFUN007247  2.1 2.3  Odorant binding 45 1.2 1.2 2.7 3.8 2.5 
AFUN001415  2.1 2.2  polypeptide N-acetylgalactosaminyltransferase 11  7.7 12 17.9 24.3 12.9 
AFUN010918   2.1 3.2   Cytochrome P450, CYP6N1 18.7 29.6 43.3 86.6 21.6 
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AFUN007143 2.5  2.2  alkaline phosphatase 18.7 42.2 35.1 59.7 22.9 
AFUN009142 2.9  2.4  aminopeptidase Ey-like  20.2 52.4 32.2 70 16.8 
AFUN003099 3.8  3.2  arginase 6.6 22.6 13.5 30.8 7.8 
AFUN000422 2  2.1  Carboxylesterase 0.8 1.4 0.9 2.4 0.7 
AFUN007080 2.2  3.7  caspase-9  5.7 11.1 11 30.8 8.3 
AFUN014849 2  2  CCR4-NOT transcription complex subunit 11 5.8 10.5 10.1 17.2 10.6 
AFUN008239 2.4  3.9  cytosolic sulfotransferase 3-like isoform X2  15.3 33.6 33.7 86.1 21.7 
AFUN007291 2.4  2.1  glutathione S-transferase GSTT2? 13.8 30.2 28.4 42.6 20.6 
AFUN015936 2.6  2.7  Gustatory receptor for sugar taste 64a 4.9 11.4 9.5 19 6.4 
AFUN006160 2.8   2.5   oocyte zinc finger 6-like 4.1 10.5 8 15.2 9.4 
AFUN015810 2.4 3.6   glutathione S-transferase, GSTE4 69.1 151.6 276.7 164 69.6 
AFUN002514 5.5 3.6   Carboxylesterase 32.2 160.5 130.6 67.5 43.9 
AFUN000001 3.7 2.1     probable chitinase 3 26 85.8 60.5 64.5 15.8 
AFUN007549   2.9   5.2 cytochrome_P450 CYP9K1 35.5 36.5 115.9 102.8 212 
AFUN002602 2.1    cytochrome b561 domain-containing 2 34.5 65.2 50.3 87.9 41.2 
AFUN007526 2.3    cytochrome c oxidase assembly COX19 17.1 35.6 30.4 28.8 29.9 
AFUN015723 2    Cytochrome P450, CYP6AH1 22.2 40.5 32 55.9 21.1 
AFUN006288 2.6    glycine dehydrogenase (decarboxylating)  57.3 133.8 81.8 157.2 68.4 
AFUN008852 2    
Glycosyltransferase involved in cell wall 
bisynthesis 
6.6 12 12.9 18.7 14.3 
AFUN002311 2.1    monothiol Grx4 family 76.3 141.2 126.6 175.9 142.7 
AFUN007415 2.3    7 kDa salivary gland allergen 153.3 313.8 305 276.8 104.5 
AFUN004413 2.1    nucleoporin NDC1 isoform X1 12.9 25.1 22.9 32.7 23.4 
AFUN008376 2.1    V A-type H+-transporting ATPase subunit B 245.5 473.3 298.5 400 484.2 
AFUN008872 2.4       Zinc carboxypeptidase 191 412.8 367.9 356.6 289.7 
AFUN009750  2   alkaline phosphatase 7.6 8.9 17.1 20.7 14.5 
AFUN002978  2   Cytochrome P450, CYP314A1 5.3 8.3 12.2 15.2 10.8 
AFUN008819   2     glutathione S-transferase, GSTMS3 8 4.8 18.3 17.1 6.4 
AFUN001429   2.4  alkaline phosphatase 3.7 5.6 3.1 13 2.7 
AFUN010814   2.5  Alpha beta hydrolase family 0.8 0.8 0.4 2.8 0.7 
AFUN004002   2.4  argininosuccinate lyase 177.4 257 252.8 616.9 170.4 
AFUN007079   2.9  caspase-9  18.5 33.3 29.2 78.8 21.8 
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AFUN009199   2.5  chitin synthase 19.8 27.3 42.3 71.3 34.7 
AFUN014173   2.7  chymotrypsin-like elastase family member 2A 13.2 21.8 19.9 51.8 18.1 
AFUN004870   2.7  chymotrypsin-like elastase family member 2A 3.5 3.9 7.6 13.5 6.5 
AFUN015895   2.4  Cytochrome P450, CYP4H25 3.3 2.5 4.5 11.7 3.6 
AFUN015785   2.2  Cytochrome P450, CYP6AA2 9.1 13.8 15.4 29.6 11 
AFUN015909   2.3  cytochrome P450  3 4.4 5 9.7 6 
AFUN015841   2.2  glutathione S-transferase GSTD4 4.4 2.3 6.5 13.9 3.8 
AFUN015768   2.3  glutathione S-transferase, GSTD11 13.5 21.5 27.9 45 14.4 
AFUN008560   2.6  glutathione S-transferase 8.4 11.3 17 31.6 18.2 
AFUN002910   3.4  lipase member H-like 2.1 2.7 1.9 10.6 1.9 
AFUN007911   2.1  Solute carrier family 46 member 3 40.4 60.9 82.1 120.7 58.6 
AFUN009946   3.6  Chymotrypsin-elastase inhibitor ixodidin 0.1 0.1 0.1 0.4 0.1 
AFUN007416   2.7  37 kDa salivary gland allergen  4.2 7.3 5.8 16.7 4.5 
AFUN015951   2.7  Gustatory receptor 8a 1.2 1.2 0.8 4.9 1.5 
AFUN010684   3.6  Cuticular protein RR 0.1 0.19 0.03 0.34 0.18 
AFUN016007   3.1  Gustatory receptor for sugar taste 43a 1 1.5 0.7 4.4 1.3 
AFUN015901   2.2  Odorant receptor Or2  2.6 1.9 1.5 8.2 2.3 
AFUN008524   2.2  Odorant receptor 22c 2.1 2.2 1.1 6.8 1.5 
AFUN015721   2.6  Odorant receptor 4  1.1 1.2 0.6 4 1 
AFUN010920   5.5  cytochrome P450 partial, CYP6M1b 0.18 0.09 0.1 0.99 0.13 
AFUN015933   3.2  gustatory receptor 2a 0.5 0.8 0.6 2.1 1 
AFUN008427   2.1  Gustatory receptor for sugar taste 64a 3.8 6.4 5.8 11.8 3.1 
AFUN000851   3.1  N-alpha-acetyltransferase 40 2.3 3.8 3.3 10.2 2.7 
AFUN001353   2.4  odorant-binding OBP56d- partial 0.9 0.5 0.7 3.1 1 
AFUN010884   2  oocyte zinc finger 6-like 6.2 10.8 12.3 18.5 14 
AFUN000174   3.5  peritrophin-1 [Culex quinquefasciatus] 1.2 0.8 1.4 5.8 2.5 
AFUN015801   2.5  cytochrome P450, CYP6P2 27.3 23 36.9 98.9 16.8 
AFUN010874   2  zinc finger 2 homolog isoform X1  8.5 13.6 14.2 25.3 15.2 
AFUN007113   2  zinc finger 2 homolog isoform X1  6.6 8.3 11 19.5 11 
AFUN014520       2.1 
CCR4-NOT transcription complex subunit 7 
isoform X1 
12.2 21.1 23.7 20.3 29.1 
AFUN006799    45 lipase member H-like 0 0 0 0 15.8 
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AFUN011526    2.2 
microtubule-associated RP EB family member 3 
isoform X2  
17.2 23.1 32.4 44.1 42.7 
AFUN000877    2 OR94A_DROME ame: Full=Odorant receptor 94a 4.9 4.7 5.8 10.5 11.5 
AFUN006418    4 cuticular_protein_RR-3_family_(CPR111) 0.7 1.2 0.8 1.3 3.3 
AFUN011733    2.8 Carboxylesterase 13.6 23.9 23.4 37.7 44.4 
AFUN005433       2.1 solute carrier family 35 member F5  11.4 11.3 23.5 22.7 27.3 
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Table S3.  Descriptive statistics of Whole genome POOLseq sequence read data  
 
Sample name 
Untrimmed 
reads 
Trimmed reads R1/R2 pairs 1 R0 reads (%) 2 
FUMOZ 98,333,448 97,312,008 48,166,137 979,734 (1.01%) 
FANG 103,497,770 102,476,042 50,736,627 1,002,788 (0.98%) 
MWI-PER-060-DEAD-A 122,744,088 121,558,527 60,196,626 1,165,275 (0.96%) 
 
1 Forward (R1) and reverse (R2) read pairs after trimming 
2 Reads unpaired after trimming (% of total trimmed reads) 
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Table S4:  Counts of reads aligned at the left and right breakpoints of the 6.5 kb insertion supporting different haplotypes 
Location/Colony Year Genomes 
Insertion 
(left) 
Insertion 
(right) 
Deletion 
(left) 
Deletion 
(right) 
“Parental” 
(left) 
“Parental” 
(right) 
FUMOZ n/a 38 43 44 0 0 22 16 
FANG n/a 40 0 0 24 30 15 23 
Malawi 2014 40 11 15 0 1 9 12 
“Insertion”=insertion present between CYP6P9a and b; “Deletion”=insertion absent between CYP6P9a and b;  
“Parental”=read originating from elsewhere in the genome, from where the inserted sequence was derived. 
 
 63 
 
Table S5: Population genetic parameters of the 800bp fragment upstream of CYP6P9a 
 
Total N S h hd  k D  D*  
Malawi Pre-bednet 24 61 19 0.97 0.027 18.26 0.13ns 0.14ns 
Mozambique Pre-bednet 15 25 12 0.96 0.012 8.36 0.36ns -072ns 
Total Pre-bednet 39 74 30 0.98 0.025 17.21 -0.28ns -1.04ns 
Malawi Post-bednet 18 4 2 0.11 0.00066 0.44 -1.85* -2.5* 
Mozambique Post-bednet 34 3 4 0.365 0.0008 0.53 -0.6ns 0.93ns 
Total Post-bednet 52 7 5 0.283 0.00077 0.52 -1.74ns -1.90ns 
Total all 91 76 34 0.72 0.019 13.1 -0.62 -1.94 
N= number of sequences (2n); S, number of polymorphic sites; h, number of haplotypes; hd, 
haplotype diversity; , nucleotide diversity (k= mean number of nucleotide differences); D and D* 
Tajima’s and Fu and Li’s statistics; ns, not significant; * significant P<0.05. 5 
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Table S6: Correlation between genotypes of CYP6P9a and mortality (PermaNet 2.0) and blood feeding after the 
experimental hut trial with the FANG/FUMOZ strain 
 
 
 OR P CI 
  Mortality   
Unfed RR vs SS 34.9 <0.0001 15.8-77.1 
 RS vs SS 19.9 <0.0001 9.7-40.9 
 RR vs RS 1.75 0.26 0.81-3.8 
 R vs S 6.25 <0.0001 3.3-11.7 
All samples RR vs SS 10.82 <0.0001 5.6-20.8 
 RS vs SS 5.3 <0.0001 2.8-9.8 
 RR vs RS 2.04 0.0002 1.1-3.7 
 R vs S 3.17 0.02 1.78-5.65 
Blood feeding 
PermaNet 2.0 RR vs SS 1.75 0.19 0.82-3.7 
 RR vs RS 2.5 0.052 1.09-5.75 
 RS vs SS 0.7 0.67 0.28-1.7 
 R vs S 1.43 0.26 0.82-2.5 
PermaNet 3.0 RR vs SS 4.54 <0.0001 2.3-8.7 
 RR vs RS 2.6 0.0012 1.43-4.7 
 RS vs SS 1.74 0.17 0.87-3.47 
 R vs S 2.14 0.18 1.17-3.19 
 10 
Mortality rates were assessed only for PermaNet 2.0 because mortality levels were very high for PermaNet 3.0. 
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Table S7: Primers used for characterization of the promoter of CYP6P9a 
Primer name sequence 
6P9a1F TCCCGAAATACAGCCTTTCAG 
6P9Ra/b TACACTGCCGACACTACGAAG 
6P9a5F AGCGGAAGGGGTTTTTGTAG 
6P9a5R CTTCTGTGATGCCCCAAAAT 
6P9a3.2F CAATGCTGCTTTCCTTCACA 
SacIFU-6P9a0.8  CGAGCTCGTCCCGAAATACAGCCTTTCAG 
SacIFU-6P9a0.5F        CGAGCTCGATCCCTAACTATTAAAAGGCAAT 
SacIFU-6P9a.03F     CGAGCTCGTGCAGGGAAAAGGAGGACAT 
Sac1FU-6P9a0.15F     CGAGCTCGCACGCACACTGACATGATGT 
MluIFU-6P9Ra/b  CGACGCGTCGTACACTGCCGACACTACGAAG 
KpnIFA-6P9a0.8F     CGGGGTACCCCGTCCCGAAATACAGCCTTTCAG 
KpnIFA -6P9a0.5F CGGGGTACCCCG ATCCCTAACTATTAAAAGGCAAT 
KpnIFA -6P9a0.3F   CGGGGTACCCCGTGCAGGGAAAAGGAGGACAT 
KpnIFA -6P9a0.15F   CGGGGTACCCCGCACGCACACTGACATGATGT 
HindIII -6P9Ra/b CCCAAGCTTGGGCCGTACACTGCCGACACTACGAAG 
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